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INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is an autoimmune disorder in which 
multiple systems are affected. In SLE, there is production of autoantibodies, which are 
directed against nuclear and cytoplasmic constituents of the cell.It is a chronic disease 
which manifest by periods of alternating exacerbations and remissions. SLE causes injury 
mainly to skin, joints, and kidney. In certain population the prevalence of SLE may be 
high. It is a disease which predominantly affects women in their peak reproductive period 
and is an important cause of morbidity and mortality in that age group of females. Many 
environmental, genetic and hormonal factors have been associated with the pathogenesis 
of SLE. 
SLE may present with variable symptoms which may range from skin and joint 
involvement to major organ involvement. The progression of the disease is not 
predictable. With proper therapy the disease runs a course of flare-ups and remissions 
which may extent a period of years or sometimes even decades.Corticosteroids and other 
immunosuppressants are used for treating disease exacerbations. Sometimes the course of 
SLE may be benign and without taking any medications the patients may survive for 
years. With recent advances in diagnostic and therapeutic approaches there is significant 
improvement in the outcome of SLE.  
In an individual who is genetically predisposed infections play a key role in the 
manifestation of the disease. Disease activity and infection are important causes of 
morbidity and mortality in patients with SLE. It is suggested that infections may also play 
a main part in exacerbation of disease activity in SLE. Several studies identify active 
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lupus as a risk factor for infection. SLE patients are inherently at risk for developing 
infections due to various immunological dysfunctions. Immunosuppressants which are 
used in the treatment of SLE further increases the susceptibility to infections. 
The percentage of SLE patients who develop infections range from 33% to 50%. 
Infections can develop or supervene during the course of lupus. The risk factors for 
infection in SLE have been identified in several studies and include active lupus, renal 
lupus activity, renal insufficiency, proteinuria, low albumin, corticosteroid use and 
immunosuppressive drug use. 
A widerange of infections have been reported in SLE. Bacterial infections are 
common accounting for 80% of infections. Fungal, viral and parasitic infections have 
also been recorded in SLE patients.  The most common sites of infection in many studies 
are urinary tract and respiratory tract. 
Recognition of infections is important as they may mimic SLE flares leading to a 
delay in diagnosis or inappropriate increase in doses of immunosuppressants with 
catastrophic consequences. The published articles on infections in SLE patients from 
South India are limited. Hence the present study will give an insight into the infections in 
SLE patients and also the association of infections with steroid intake.  
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AIMS AND OBJECTIVES 
 
1) To isolate and identify the various bacterial and fungal pathogens associated with 
infections in patients with SLE. 
2) To study the antimicrobial susceptibility pattern of the isolates. 
3) To correlate the association of steroid therapy with occurrence of infections in 
patients with SLE. 
4) To study the immunological profile in SLE patients.  
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REVIEW OF LITERATURE 
SLE is the prototype of a systemic autoimmune disorder in which there is 
production of autoantibodies to constituents of the cell nucleus. SLE affects almost all 
organs of the body. Thus it is a complex disease and the patients exhibit variable 
presentations, course and prognosis, remissions and exacerbations which during the 
course of SLE. 
HISTORICAL BACKGROUND 
During the middle ages the word LUPUS (Latin for “wolf”) was used to denote 
the skin lesions that were suggestive of a wolf’s bite. Lupus was an ancient Roman 
family name and there was a St. Lupus who lived in France in 600 A.D
[13]
.The word 
Lupus is attributed to the physician Rogerias Frugardi of 13
th
 century. The term 
“Lupuserythemateaux” was coined in Paris by the medical student Pierre L.Cazenave in 
1851.The visceral involvement in SLE was first recognized by Moriz Kaposi in 1872
[20]
. 
This is followed by the following milestones like the discovery of LE cell 
phenomenon by Malcom M. Hargraves, indirect immunofluorescence microscopy to 
detect autoantibodies by George Friou et al in 1957 and anti DNA antibodies detection in 
the sera of SLE patients by Tan et al in 1966
[43]
 . In 1969 Koffler et al in New York 
found that the antibodies to native double stranded DNA is more specific for SLE. A 
cytoplasmic ribonucleoprotein antigen designated Sm was detected in SLE serum by Tan 
and Kunkel in 1966 in New York
[43]
. Criteria for classification of SLE have been 
established and revised by the American college of Rheumatology in 1982
[5, 32]
. 
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The history of lupus is divided into three periods: 
a) Classical period: In 1846 the Viennese physician Von Hebra compared the malar 
rash to butterfly. He was also the one to use the term lupus erythematosus. 
b) Neoclassical period: This was marked by the recognition of lupus as a distinct 
disease with systemic manifestations. 
c) Modern period: This period was initiated by the discovery of the LE cell in 1948, 
followed by the discovery of autoantibodies, pathophysiology and improved 
therapy. 
EPIDEMIOLOGY AND CLASSIFICATION 
EPIDEMIOLOGY 
SLE was considered a rare disease till 1950s. As of 1936 five cases of SLE were 
found among 7,500 autopsies at the John Hopkins Hospital. There had been an increase 
in the number of cases since then due to increased use of the LE cell test and other 
diagnostic methods. 
The reported prevalence of SLE in India ranges from 14 to 60 per 100,000
[55]
. In 
United States the prevalence of SLE is approximately 51 per 100,000
[2]
. As a result of 
early diagnosis of SLE the incidence has increased three times in the last 40 years
[2]
.The 
female to male ratio is estimated to be around 9:1. Race also determines the 
predisposition to develop SLE, African-Americans and Hispanics are frequently affected 
than whites. The disease morbidity is also high in them
[13]
. In a study conducted in Saudis 
the sex ratio is 4.4: 1 with an average age of 35years at onset of disease
[13]
. In India the 
median age of onset of SLE is estimated to be 24.5 years and the female to male ratio 
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(F:M) is 11:1
[56]
. 65% of patients with SLE have onset of disease between the ages of 16 
and 55, 20% have onset before the age of 16 and in remaining 15% after the age of 55
[20]
. 
The features of male SLE differ in various ways from female SLE like less 
occurrence of photosensitivity, more occurrence of serositis, diagnosis at an older age and 
an increased one year mortality rate. In elderly patients with SLE, the disease is milder 
and they have a lower occurrence of clinical features like malar rash, photosensitivity, 
alopecia, renal involvement, neuropsychiatric manifestations but they have a higher 
occurrence of serositis and lung involvement
[20]
. 
The survival period for SLE patients has improved considerably; but when North 
American and European repots were compared the survival rate was low among SLE 
patients in India
[52]
. 
CLASSIFICATION CRITERIA 
In 1971 the classification criteria were developed. The criteria were revised in 
1982 and again in 1997
[20]
. The American college of Rheumatology has established the 
following criteria for SLE classification. To be classified as lupus, a patient must satisfy 
four out of eleven criteria. These criteria are valuable in clinical and laboratory 
investigation of this disease since they easily differentiate patients with Lupus from those 
with other connective tissue diseases. 
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 1997 AMERICAN COLLEGE OF RHEUMATOLOGY CLASSIFICATION 
CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS 
1) Malar rash(butterfly rash) 
2) Discoid rash 
3) Photosensitivity 
4) Oral ulcers 
5) Arthritis- Nonerosive arthritis involving two or more peripheral joints, with 
tenderness, swelling, or effusion 
6) Serositis- Pleuritis or Pericarditis 
7) Renal disorder- Proteinuria  >0.5g/dl 
8) Neurologic disorder- Seizures or psychosis without other causes 
9) Hematologic disorder- Hemolytic anemia or leukopenia or thrombocytopenia in 
the absence of offending drugs 
10) Immunologic disorder- Anti- ds DNA, anti-Sm, and /or anti-phospholipid 
11) Antinuclear antibodies- A significant titre by immunofluorescence or other assay 
in absence of drugs known to induce ANAs. 
A person shall be said to have SLE if any four or more of the eleven criteria are 
satisfied, serially or simultaneously during any interval of observation. 
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PATHOGENESIS AND ETIOLOGY 
Several genetic, environmental and immunological factors have been found to be 
associated with the pathogenesis of SLE. 
a) GENETIC FACTORS 
There are strong evidences to suggest that SLE is a genetic disease. Both MHC 
and non-MHC genes contribute to the risk of developing SLE. This is supported by 
the fact that the disease shows aggregation in family, higher rate of concordance in 
twins and finding that prevalence and severity of SLE differ between ethnic 
groups
[42]
. 
Genes associated with SLE 
1) HLA Class II alleles (HLA – DR and HLA –DQ) 
2) Complement gene defects causing deficiencies of: 
 C1q or C1r / C1s 
 C2 
 C4 (C4A and C4B), C4A 
3) Mannan-binding protein gene deficiencies 
4) Fcγ receptor alleles with differences in function:  
 Fcγ RIIA 
 Fcγ RIII 
5) Cytokine gene alleles causing differences in expression:  
 TNF – α, IL – 10, IL – 6 
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b) IMMUNOLOGICAL FACTORS 
Dendritic cells play a role in initiation and later amplification of autoimmune 
response in SLE by abnormally presenting self antigens which are derived from 
damaged and apoptotic cells to T cells. The central players of autoimmunity in SLE 
are B cells. They mediate tissue injury by producing high levels of autoantibodies. 
Also, since B cells can also act as antigen presenting cells, they internalize the soluble 
antigens and present them to T cells. There is decreased threshold and increased 
inflammatory capacity of T cells. So there is enhancement of T-cell effector 
function
[42]
. 
c) ENVIRONMENTAL FACTORS 
There are many evidences to support the association of estrogens with SLE. 
Estrogens increase the risk of SLE or cause exacerbation of disease activity. Several 
studies have documented increased risk of SLE in smokers. EBV specific immune 
responses have been implicated in SLE pathogenesis. 
Ultra violet exposure may act as a triggering factor for SLE disease flares. It has 
been found that ultraviolet light induces apoptosis of cells and the DNA is altered so 
that it becomes immunogenic
[43]
. 
AUTOANTIBODIES IN SLE 
The humoral immune response protects our body from pathogenic organisms by 
forming antibodies that either destroy or inactivate microbes and also their toxins. To do 
this function of protecting our body our immune system produces antibodies to a varied 
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array of foreign antigens, but it must do without generation of pathogenic antibodies to 
self. 
The characteristic feature of SLE is the production of high affinity antibodies that 
are able to bind self- antigens. It has been found that antibodies like anti-Sm/RNP, ANA 
are markers for disease while other antibodies are thought to play a significant role in 
pathogenesis of SLE. The pathogenicity of autoantibodies is determined by the heavy 
chain isotype. 
Even in healthy individuals a degree of autoimmunity or self-reactivity occurs. In 
autoimmune diseases the autoantibodies have high affinity for self antigens through 
somatic mutation. The other features in SLE include hyper responsiveness of B cells, 
polyclonal hypergammaglobulinemia, and there is also high antibody titres to viral 
antigens which are encountered commonly. 
The production of autoantibodies is an important feature of SLE. Autoantibodies 
in SLE are of IgG (IgG1 & IgG3) and to a lesser extent, IgM and IgA isotypes
[89]
.There is 
a polyclonal immune response to each autoantigen. 
ANAs cannot penetrate intact cell, but if cell nuclei are exposed can bind with 
them. LE bodies or hematoxylin bodies are produced when the nuclei of damaged cells 
react with ANAs, losing their chromatin pattern and becoming homogenous. LE cells are 
easily seen when blood is agitated in vitro, which is any phagocytic leukocyte engulfing 
the denatured nucleus of injured cell. In the past LE cell demonstration was used as a test 
for SLE, but it is now largely of historic interest
 [89]
. 
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SPECIFIC AUTOANTIBODIES 
Autoantibody in SLE are referred to as antinuclear antibody(ANA) 
1) ANTIBODY TO DNA AND DNA-BINDING PROTEINS 
a) Anti-DNA 
It is found that three forms of DNA are antigenic in SLE: single stranded DNA, 
double stranded DNA and left handed (Z)DNA. Anti ds-DNA antibodies are more 
specific for SLE and found in 60% of patients with SLE and they reflect disease activity. 
There has been evidence for the role of DNA-anti DNA immune complexes in the 
pathogenesis of lupus nephritis
[89]
. 
b) Antihistone and antinucleosome 
The intact DNA in eukaryotes forms a double stranded helix due to pairing between 
complementary bases on each strand and is compacted into chromatin through its 
interaction with histones and other proteins. Nucleosome is a subunit of chromatin and it 
comprises about 200 base pairs of DNA twisted around an octamer of histone (two 
molecules each of H2A,H2B,H3 and H4). Histone H1 binds on the surface and link 
adjacent nucleosomes and stabilizes the nucleosome. 
In 50-70% of SLE patients with antihistone antibodies they target the H1 and H2B 
proteins, followed by H2A, H3 and H4 usually in association with anti-ds DNA 
antibodies. In drug induced lupus these antibodies occur in association with anti ss-DNA 
antibodies. Procainamide and Quinidine induce IgG antibody reactive with (H2A-
12 
 
H2B)DNA complex. Hydralazine and Chlorpromazine induce IgM antibody that bind to 
H1, H3-H4, H2A-H2B and ss-DNA
[89] 
. 
c) Anti-Ku(nuclear factor IV) 
Ku is a heterodimer made of two proteins of 70KDa and 86KDa and has a role in 
DNA repair. Both diffuse nuclear and nucleolar immunofluorescence staining produced 
by Anti-Ku antibodies. They are found in scleroderma-myositis overlap, scleroderma and 
SLE. 
d) Anti-proliferating cell nuclear antigen(PCNA) 
PCNA is a 36KDa protein which is an auxiliary protein of DNA polymerase delta and 
it produces positive IF staining only in dividing cells
[89]
. 
2) ANTIBODIES TO RNA AND TO RIBONUCLEOPROTEINS 
a) Anti-RNA 
Autoantibodies to Single stranded (SS) and double stranded (ds)-RNA have been 
documented in 60% of patients with SLE
[89]
. 
b) Anti-Sm, Anti  RNP 
Anti-Sm antibodies are found only in SLE patients, but anti- RNP antibodies occur in 
other autoimmune disorders also. 
c) Anti-Ro (SS-A) and anti-La (SS-B) 
La is a nuclear phosphoprotein that binds to precursor transfer(t) RNAs and 5s rRNA 
and to small RNAs encoded by viruses
[89]
. Two types of Ro proteins are thoroughly 
characterized Ro60 and Ro52 and are present in both cytoplasmic and nuclear 
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compartments. Antibody to Ro 60 (SS-A) is found in 25-40% of patients with SLE and 
antibody to La (SS-B) is found in 10-15%
[89]
. Anti Ro/La antibodies are associated with 
subacute cutaneous lupus erythematosus, photosensitivity and neonatal lupus 
erythematosus syndrome. IgG anti-Ro crosses placenta and can bind to conduction 
system of fetal heart, can alter myosin-actin function and cause heart block. Most of the 
infants with congenital heart block have mothers with anti-Ro antibodies
[20]
. 
d) Antiribosomal antibodies 
Antiribosomal antibodies directed against three phosphoproteins (P proteins)- P0, P1, 
and P2 located on the large (60 S) ribosomal subunit. In SLE the prevalence of anti-Rib-P 
antibodies is reported to be around 10% to 40%
[89]
. 
3) ANTIBODIES TO CELL MEMBRANE COMPONENTS 
a) Antibodies to blood cells 
       SLE patients have autoantibodies directed against red cells, platelets, and 
lymphocytes. 
b) Antineuronal antibodies 
IgG and IgM antibodies that bind to the surface of neuroblastoma cells in vitro and 
other neuronal antigens have been detected in the serum of patients with SLE
[89]
. The 
presence of IgG antineuronal antibodies in the CSF correlate best with CNS involvement 
in SLE. 
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c) Antibodies to stress or heat shock proteins (hsp) 
IgM antibodies to the 73 KDa member of the hsp 70 family and IgG antibodies to hsp 
90 families have been identified in a small proportion of patients with SLE but their 
pathogenic significance remains to be established
[89] 
. 
d) Antiphospholipid antibodies (aPL antibodies) 
They form a heterogenous group and are directed against anionic phospholipids (PL) 
or protein-phospholipid complexes. They are called lupus anticoagulants(LACs) because 
they prolong phospholipid dependent coagulation assays
[62]
. aPL antibodies occur in  
40% -50% of SLE patients. The antibodies against the phospholipid-β2-glycoprotein 
complex have the ability to bind cardiolipin antigen which is used in serological test for 
diagnosing syphilis. SLE patients may therefore give false-positive test result for syphilis.  
DETECTION OF ANA 
1. INDIRECT IMMUNOFLOURESCENCE METHOD 
The indirect immunofluorescence ANA test (FANA) provides a sensitive screening 
method for ANA detection
[89]
. Test sera at varying dilutions are incubated with substrate 
cells and bound antibodies are detected by fluorescein conjugated anti-human Ig followed 
by visualization under a fluorescence microscope. Its reliability depends primarily on the 
choice of substrate, which may vary from rodent liver or kidney frozen sections to 
cultured proliferative cell lines, most commonly the human epithelial tumor cell line 
HEp2. 
Because different ANAs have different intracellular targets, clinically useful 
information may be obtained by observing the fluorescence pattern in the nucleus, 
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nucleolus or cytoplasm. Nuclear patterns include homogenous, rim and speckled staining. 
Nucleolar patterns include discrete speckled, grainy speckled and clumpy staining. 
Normal individuals usually older and female persons or relatives of persons with 
connective tissue diseases positive FANA results at a frequency of upto 30% although 
their titer generally remains below 1:320  and the pattern is often homogenous. 
 
2. IMMUNODIFFUSION (ID) 
The double immunodiffusion Ouchterlony technique provides a crude method for the 
detection of autoimmune serum specificity by the comparison of precipitin activity with 
prototype antisera. Although ID provides a simple method for the detection of specific 
autoantibodies, its low sensitivity compared with newer assays limit its widespread 
use
[89]
. 
 
3. COUNTERIMMUNOELECTROPHORESIS (CIE) 
The CIA technique modifies the ID method to give greater sensitivity. Acidic 
antigens such as DNA or RNA are electrophoresed from a cathode well and antibodies 
from an anode well. A precipitin line forms as specific autoantibodies encounter antigen. 
Because this method also provides limited sensitivity with a limited repertoire of 
autoantibody detection, it has largely become supplanted by other methods of ANA 
detection
[89]
. 
4. ELISA 
ELISA provides a highly sensitive and rapid technique for the detection of ANAs and 
antibody specificity. Sometimes ELISA tends to produce false positive results and 
confirmation requires further testing. 
 
16 
 
5. IMMUNOPRECIPITATION 
Radio immunoprecipitation assays provide sensitive and specific means to detect 
autoantibodies. 
6. IMMUNOBLOTTING 
Western blotting assays use autoimmune serum as probes against membranes 
containing electrophoretically resolved purified or crude antigens. Bound antibodies are 
detected by an enzyme linked antihuman IgG antibodies and substrate dependent colour 
development. 
ANTI- DNA ANTIBODY TESTS 
1. FARR RADIO IMMUNO ASSAY (RIA) 
The Farr RIA, which resembles immunoprecipitation assays involves the binding of 
autoantibodies to radio labeled ds DNA in solution and this assay is generally considered 
to be the gold standard for anti ds DNA analysis
[89]
. 
2. CRITHIDIA LUCILIAE TEST 
Crithidia luciliae test provides an inherently reliable ds DNA substrate. In this assay, 
the hemoflagellate Crithidia luciliae serves as a substrate for indirect 
immunofluorescence. Its kinetoplast, a modified giant mitochondrion contains a 
concentrated focus of stable, circularized ds DNA without contaminating RNA or 
nucleoproteins providing a sensitive and fluorescent substrate to establish anti ds DNA 
activity
[89]
. 
3. ELISA 
ELISA kits are now available for detecting anti ds DNA antibodies. 
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CLINICAL FEATURES 
The clinical features of SLE are variable from general manifestations to organ-
specific manifestations. 
GENERAL MANIFESTATIONS 
The general manifestations in SLE patients include malaise, fatigue, fever, weight 
loss and anorexia.  
CUTANEOUS MANIFESTATIONS 
Cutaneous manifestations in SLE are classified as Lupus Erythematosus (LE) specific 
and LE non specific. 
a) LE specific lesions 
LE specific lesions in SLE can be classified into acute, subacute and chronic lesions. 
Acute lesions: Acute lesions may present as localized or generalized lesions. Butterfly or 
malar rash is a localized skin lesion in SLE
[4]
. 
Subacute Cutaneous Lupus Erythematosus (SCLE): SCLE denotes the cutaneous 
lesion which is widespread in distribution, photosensitive and non-scarring
[4]
. 
Chronic Lupus: Chronic lupus manifest as discoid lesions in the absence of other 
systemic symptoms and known as discoid lupus. They may also be a disease 
manifestation of SLE
[4]
. 
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b) LE non-specific lesions 
The non-specific lesions correlate with lupus activity and include alopecia, 
vesiculobullous lesions, urticarial lesions and vasculitic lesions.  
Photosensitivity 
Photosensitivity may occur in more than 50% of patients with SLE
[4]
. 
MUSCULOSKELETAL MANIFESTATIONS 
a) Arthritis 
Arthritis is one of the most common manifestations in SLE. The joint involvement 
may be in the form of arthritis, arthralgia or both and is classically non-erosive and non-
deforming involving small joints of the hands, wrists and knees
[20]
. 
b) Myositis 
Myositis is one of the causes of myalgia in SLE patients. Myositis of proximal 
muscles is found to occur in 5% to 11% of patients
[82]
. 
c) Osteonecrosis 
Osteonecrosis is common in younger age group and present early in the disease 
course. Symptomatic osteonecrosis occurs in 5% to 12% of patients with SLE
[23]
. 
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RENAL MANIFESTATIONS 
Renal involvement occurs in about 40% to 70% of SLE patients
[20]
. It is also a 
major cause of morbidity and mortality in them. Renal biopsy is done to find the 
histologic class of Lupus Nephritis (LN). 
TABLE I:Histologic classification of Lupus Nephritis 
WHO TYPE  
CLASS I Minimal mesangial lupus nephritis 
CLASS II Mesangial proliferative nephritis  
CLASS III Focal lupus nephritis  
CLASS IV Diffuse lupus nephritis 
CLASS V Membranous lupus nephritis 
CLASS VI Advanced sclerotic lupus nephritis 
The above classification is as per the International Society of Nephrology / Renal 
Pathology Society. 
Patients with membranous glomerulopathy have proteinuria, C3tends to be normal 
and anti-DNA antibodies are found in low titres. But patients with proliferative nephritis 
have hypertension, a nephritic urine sediment with proteinuria, low C3 and high titres of 
anti-DNA antibodies. 
Prognosis varies among the clinical and pathologic forms of lupus nephritis. The 
factors associated with bad outcomes include African-American race, azotemia, anemia, 
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APS, failure to respond to initial immunosuppressive therapy and flares with worsening 
in renal function
[9, 60].
 
NEUROPSYCHIATRIC MANIFESTATIONS 
Nervous system involvement is a major cause of morbidity and mortality in SLE. 
SLE affects the CNS and the peripheral nervous system. The syndromes involving 
nervous system in SLE are collectively called neuropsychiatric systemic lupus 
erythematosus (NPSLE) syndromes
[3]
. Cognitive dysfunction is reported in 80%, 
psychosis in 8%, generalized and focal seizures in 6% to 51% and peripheral neuropathy 
in 28% of SLE patients. 
CARDIAC MANIFESTATIONS 
Pericarditis is the most common manifestation in SLE.  
PULMONARY MANIFESTATIONS 
The pulmonary manifestations include abnormal pulmonary function, pulmonary 
hemorrhage, pulmonary embolism, lupus pneumonitis and pulmonary hypertension
[4]
. 
LYMPH NODE AND SPLEEN INVOLVEMENT 
Lymphadenopathy occurs in 40% of SLE patients usually at disease onset or 
during disease flares. Splenomegaly occurs in 10% to 45% of patients during active 
disease
[20]
. 
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HEMATOLOGIC ABNORMALITIES 
a) Anemia 
Anemia occurs in about 50% of SLE patients. The causes of anemia in SLE patients 
include anemia of chronic disease, iron deficiency anemia and autoimmune hemolytic 
anemia
[4]
. 
b) Leukopenia 
Leukopenia is common in SLE and usually associated with disease activity. A WBC 
count of less than 4,500 / µL is reported in 50% of SLE patients, especially patients with 
active disease. Lymphocytopenia occurs in 20% of SLE patients. Decreased eosinophil 
and basophil counts are secondary to corticosteroid use in lupus. Leukocytosis can occur 
in lupus and reflects an infection or the use of corticosteroids in high doses
[20]
. 
c) Thrombocytopenia 
Mild thrombocytopenia occur in about 25% to 50% of SLE patients
[20]
. 
LIVER AND GASTROINTESTINAL TRACT INVOLVEMENT 
Gastrointestinal manifestations have been reported in 25% to 40% of patients with 
SLE and could be due to either lupus of the gastrointestinal tract or the effects of 
medications
[20]
. 
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OPHTHALMIC INVOLVEMENT 
Retinal vascultitis occurs in a small percentage of SLE patients and is usually 
associated with active disease
[20]
. 
TREATMENT OF SLE 
SLE is not a curable disease and it is rare to see complete remissions. The 
treatment plan is therefore to control severe exacerbations of disease and to develop 
subsequent maintenance strategies to suppress symptoms and prevent organ damage. 
Treatment of mild SLE without major organ involvement 
Nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial 
(hydroxychloroquine), glucocorticoids and in severe cases immunosuppressive agents 
(azathioprine, mycophenolatemofetil, methotrexate) are used.  
Treatment of moderate to severe SLE 
Treatment consists of a period of induction therapy in which intensive 
immunosuppressive therapy is given to the patient and this is followed by a longer period 
of maintenance therapy using less intensive immunosuppressants
[9]
. 
Corticosteroids 
For patients with moderate to severe disease corticosteroids are used either as 
single or as background therapy in combination with immunosuppressive agents at 
prednisolone doses ranging from 0.5 - 1.0 mg / kg / day in a single dose followed by 
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tapering of dosage. In cases of doses more than 0.6 mg / kg / day or in rapidly 
progressing severe disease bolus therapy is used (1000 mg of methylprednisolone IV 
daily for three days followed by 0.5 mg / kg / day of prednisolone
[20]
 
Azathioprine 
In moderate to severe SLE, Azathioprine is used at doses of 1 - 3 mg / kg / day
[20]
. 
MycophenolateMofetil (MMF) 
MMF is used to treat manifestations of SLE like proliferative nephritis, skin 
disease, refractory thrombocytopenia and pulmonary haemorrhage in patients refractory 
to corticosteroids or cytotoxic agents
[20]
. 
Cyclophosphamide 
Intermittent pulse cyclophosphamide therapy (IV cyclophosphamide) is effective for 
moderate to severe proliferative lupus nephritis. The treatment can be given as follows. 
(1) Once monthly IV for 6 months followed by two years of quarterly doses,  
(2) Cyclophosphamide for 12 weeks followed by azathioprine 
(3) Cyclophosphamide for 6 months followed by azathioprine or 
mycophenolatemofetil
[48]
. 
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Rituximab 
Rituximab is an anti-CD20 chimeric murine / human monoclonal antibody that 
depletes B cells but not plasma cells – resulting in peripheral blood B cell 
lymphopenia
[20]
. 
Other Drugs used in the treatment of SLE 
 Methotrexate 
 Cyclosporine 
 Intravenous Gamma Globulin 
INFECTIONS IN SLE 
SLE patients are prone to develop infections due to the underlying immunological 
dysfunctions. The immunosuppressive agents that are used in treating sever disease 
manifestations further increases this risk of infections. 
SLE mortality from infections 
In reviewing mortality from a forty year period, Hellman et al. attributed 27% of 
deaths in SLE patients to infections. In another study by Klemperer et al. infection was 
the cause of death in 40% of SLE patients. In a large multicenter study of 1103 patients 
with SLE 33% of the deaths were caused by infection, and infection was a contributing 
cause in 10% of patients
[77]
. When clinical and demographic features such as age, 
socioeconomic status and race were considered infection was the leading cause of death 
in all groups (39%) by Reville et al.
[74]
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A 1993 report from Thailand documented infection as the cause of death in 23 of 
77 patients with SLE
[13]
. In European and Asian series reported in the late 1990s, despite 
wide ranges in case fatality rates of 4.5% to 24%, the proportion of deaths attributed to 
infection was similar, ranging from 20.5% to 32.5%
[13]
. In a case-control study done by 
Irastorza et al. to identify major infections in 83% SLE patients infection was the cause 
of death in 8 patients
[25]
. 
Reveille et al.
[74]
, Breban et al.
[10]
, Abu Shakra et al.
[2]
, Bellomio et al.
[7]
and Mok 
et al.
[59]
have ranked infections as the first cause of death in patients with SLE whereas 
infection was ranked as the second cause of death in patients with SLE by Urmanand 
Rothfield
[84]
, Feinglass et al.
[19]
, Wallace et al.
[87]
, Halberg et al.
[27]
, Hashimoto et al.
[29]
 
and Michet et al. 
[57]
. 
Rates of infections in SLE 
In a Swedish study in 1985, Nivel et al
[13]
 found an overall infection rate of 142 
per 100 patient years of SLE. The 1974 report of hospitalized SLE patients by Staples et 
al
[79]
 identified an overall culture verified infection rate of 1.22 per 100 hospital days.The 
most common infection site was the urinary tract. A 1991 review of infections in 
hospitalized SLE patients found an infection rate of 1.94 per 100 hospital days. In a 
recent study, serious infections developed in one-third of lupus patients during follow-
up
[25]
. In a study conducted in Korea 38% had at least one episode of infectious disease 
and the incidence of infectious disease was 4.4/100 patient-years
[39]
. H-Al-Rayes et al. 
reported infections in 58.79% of SLE patients in their retrospective study
[26]
. 
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Factors influencing susceptibility of patients to infection 
Many investigators agree that treatment with corticosteroids, as well as some 
manifestations of active SLE itself play important role as risk factors that predispose to 
infections in SLE patients. Even in the absence of corticosteroid, infections are common 
in SLE patients. Specific renal measures notably active urinary sediment was a 
significant predictor of infection. Nephritic syndrome and uremia associated with an 
increase but not significant incidence of opportunistic and bacterial infections
[92]
. 
A strong association was found between blood urea nitrogen and infections 
suggesting poor renal function are more important than renal inflammation. An increased 
tendency to develop bacterial and opportunistic infections is documented even among 
patients with SLE in clinical remission
[34]
. 
In a study done in Singapore, an increase in bacterial infections was observed 
among patients with SLE compared to normal controls, whereas the incidence of fungal 
and viral infections was similar in controls and patients with SLE
[66]
. 
Other abnormalities which account for this susceptibility to infection include 
reduction in immunoglobulin, defects in chemotaxis, phagocytic activation and delayed 
hypersensitivity, acquired and inherited deficiency of complement. Activation and 
consumption of complement and the role of specific complement components has been 
defined in SLE. C3 deficiency associated with increased risk of recurrent or disseminated 
bacterial infections. Hereditary deficiencies of complement components also have been 
described in patients with SLE
[71]
. Repeated skin and upper airway infections, 
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Haemophilus influenza septicemia and bacterial meningitis  occur due to autosomal 
recessive defects in c1q, c1r and c2 production and homozygous deficiencies of c2. 
Patients with decreased complement components C5-9 are prone to infections with 
encapsulated organisms such as Neisseria species. Patients with SLE who had a serum 
inhibitor of C5 derived chemotactic activity had increased incidence of infections
[30]
. 
Abnormalities of reticuloendothelial function also occur in SLE patients. The 
circulating immune complexes cause saturation of Fc receptors in liver and spleen thus 
preventing clearance of opsonized bacteria. This may be the cause of pneumococcal 
bacteremia and chronic Salmonella carrier state seen in some patients with SLE. The 
incidence of Herpes Zoster is increased in patients with SLE compared with normal 
individuals which may be due to abnormalities of cellular immunity
[61]
. 
Staples et al
[79]
 found that the infection rate in hospitalized patients increase from 
0.43 to 1.63 per 100 hospital days with increase in steroid dose from zero to >50 mg/day. 
In the Downstate study five fold increase in frequency of infection was found, ranging 
from 35 to 179 per 100 patient-years as average prednisone dose increased from zero to 
greater than 40mg/day. 
Risk factors for infection were glomerulonephritis, severe flare, corticosteroids, 
cyclophosphamide and plasmapheresis
[13]
. Corticosteroids predispose to infection by 
affecting host responses to microorganisms which include a decreased inflammatory 
response, decreased effector cell response in cell mediated immunity, lysis of lymphoid 
follicles and decreased immunoglobulin synthesis. 
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Prolonged steroid administration increases risk of infection by causing chronic 
changes in tissues such as skin atrophy which allow increased access of microorganisms 
into the circulation. A regimen of alternate day steroid administration is believed to 
decrease risk of infection
[13]
. Other immunosuppressive agents like azathioprine and 
cyclophosphamide are implicated as risk factor for infection in patients with SLE
[13]
.  
A French study of cytolytic therapy in rheumatic diseases failed to find an 
increased risk of infection, with the exception of Herpes virus, which was associated with 
a 10% to 20% incidence of infection compared with 2% in patients not treated with 
immunosuppressants. A prospective study in Singapore did not show an association of 
cytotoxic therapy and infection in patients with SLE
[66]
. 
It was found that patients treated with plasmapheresis and cyclophosphamide had 
more chances of developing infections compared to patients treated with 
cyclophosphamide alone. Recent clinical trials suggest infections are less frequent in 
patients treated with Mycophenolatemofetil as compared to Cyclophosphamide
[13]
. 
SPECIFIC TYPES OF INFECTIONS 
Bacterial infections 
Of all the infections occurring in SLE patients, bacterial infections are the 
commonest accounting for 50%
[13]
. The most common sites of bacterial infections are 
similar in SLE patients and in persons without SLE which include urinary tract, 
respiratory tract and skin. H-Al-Rayes in their retrospective study in SLE patients 
observed that   bacterial infection was predominant (78.6%). This is followed by viral 
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(28.2%) and fungal (28.2%) infections
[26]
. The most common organisms isolated are 
Staphylococcus aureus, Escherechia coli, Klebsiella spp. and Pseudomonas spp. In 
hospitalized patients with SLE bacteremia is common
 [13]
. 
In a recent study the most common infections reported were pneumonia, 
bacteremia and skin and soft tissue infections. The most frequent isolates in this study 
were Escherichia coli, Staphylococcus aureus, Mycobacterium tuberculosis and 
Streptococcus pneumoniae
[25]
. 
The organisms which cause infections in healthy individuals occur with 
increasing frequency in unusual sites in patients with SLE. Opportunistic infections 
caused by Salmonella typhimurium and Salmonella enteritidis have also been reported in 
patients with SLE. Infection with Listeria monocytogens is also documented and is 
associated with risk factors like renal failure, disease flare, and other 
immunosuppressants. Tuberculosis (TB) is also common in SLE. In a study done by Fang 
and Tan, TB was found in 5% of patients with SLE. A recent study reported 
extrapulmonary and military TB as common in patients with SLE
[13]
. 
Skin involvement due to Atypical Mycobacteria is rarely reported in patients with 
SLE. There are also few case reports of unusual bacterial infections like Legionnaire’s 
disease, Campylobacter endocarditis, Toxic shock syndrome and Pseudomonas 
pseudomallei meningitis. Infection with Treponema pallidum may occur, although false 
positive serologic tests for syphilis occur in SLE
[13]
. 
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Viral infections 
The most common specific viral infection in patients with SLE is Herpes zoster. 
The incidence in Western countries ranges from 3% to 21%, which is higher than that 
observed in general population. In a study conducted in Japanese patients with SLE, 43% 
incidence has been reported. Herpes simplex associated with esophageal and perianal 
lesions are also common in patients with SLE. Other viruses associated with infection in 
SLE patients include Cytomegalovirus, Human Papilloma Virus (HPV) and Parvovirus 
B19
[13]
. 
Fungal infections 
The most common fungal infection is caused by Candida spp., mostly presenting 
with oral thrush. Esophageal candidiasis may co-exist with Herpes simplex. The risk 
factors for the development of deep fungal infections in SLE patients include 
corticosteroid and immunosuppressive therapy and most common organisms are Candida 
spp. and Cryptococcus. Zygomycosis is associated with thrombotic thrombocytopenic 
purpura, CNS complications and increased mortality rate. Infections with Aspergillus spp 
have also been documented. There are case reports of fatal Aspergillus meningitis and 
septicemia in patients with SLE. Other fungal infections reported in SLE patients are 
Coccidioidomycosis, Nocardia infections, disseminated histoplasmosis and 
maduramycosis. Wei-I Tsai et al.
[88]
 in their study on invasive fungal infections have 
reported the most lethal species in the following order - Cryptococcus, Aspergillus spp. 
and Candida spp. 
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Parasitic infections 
Strongyloides stercoralis hyperinfection mimicking an SLE flare may occur. One 
case each of Visceral leishmaniasis and Paragonimiasis have been reported. Infection due 
to Toxoplasma gondii have also been reported
[13]
. 
A high index of suspicion is essential as the symptoms of SLE and infection are 
often similar. The helpful clues which help to diagnose infections are presence of the 
following like chills, leukocytosis, increased C Reactive Protein (CRP) levels
[80]
and 
absence of SLE involving multiple systems. Hence SLE patients are at high risk for 
developing infection. So all fevers must be evaluated in SLE patients because the most 
common causes of fever in them are infections and active lupus. Also the signs of 
inflammation in these patients may be altered by steroids and NSAIDs which are used for 
treating disease manifestations. Thus careful use of steroids and other 
immunosuppressive agents in SLE patients is recommended to limit infections.  
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MATERIALS AND METHODS 
PLACE OF STUDY 
This cross sectional study was conducted in the Institute of Microbiology, Madras 
Medical College in association with Department of Rheumatology, and Department of 
Nephrology, Rajiv Gandhi Government General Hospital, Chennai. 
STUDY PERIOD 
The study period was for one year from September 2011 to October 2012. 
ETHICAL CONSIDERATION 
Approval was obtained from the Institutional Ethical Committee before the 
commencement of the study. Informed consent was obtained from the study population. 
All patients satisfying the inclusion criteria were documented. Patients were interviewed 
by structured questionnaire. 
STUDY POPULATION 
Total of 110 patients fulfilling the 1982 revised American Rheumatism 
Association criteria for the classification of SLE with clinically suspected infections were 
included in the study. 
CASE DEFINITION 
Infection in SLE patients is suspected based on clinical data like fever, lower 
abdominal pain, frequency / pain during urination, cough with expectoration, loss of 
weight, and skin lesions. 
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EXCLUSION CRITERIA 
SLE patients with malignancy, transplant recipients, prolonged antibiotic therapy, 
and HIV were excluded from the study. 
DATA COLLECTION 
Data collection included age, sex, and duration of SLE, clinical features, 
laboratory investigations, and steroid/cytotoxic therapy. 
STATISTICAL ANALYSIS 
Statistical analyses were carried out using Statistical Package for Social Sciences 
(SPSS) and graphpad software by a statistician. 
SAMPLE COLLECTION, TRANSPORT AND PROCESSING 
Under strict aseptic precautions, samples were collected from the patients and 
transported immediately to the laboratory and sample processing was done. 
SAMPLES COLLECTED 
1) Urine 
2) Sputum 
3) Bronchoalveolar lavage (BAL) 
4) Ascitic fluid 
5) Cerebrospinal Fluid (CSF) 
6) Oral scrapings 
7) Nail 
8) Pus 
9) Blood 
10) Faeces 
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COLLECTION OF SAMPLES 
Urine 
Freshly voided clean catch midstream urine samples were collected in sterile wide 
mouthed containers. 
Sputum 
The patient was asked to rinse out the mouth with water, then to cough deeply to 
expectorate a sample of lower respiratory secretions. Early morning sputum sample was 
collected
[63]
. 
Bronchoalveolar lavage (BAL) 
A flexible bronchoscope is inserted and a segment of lung was washed with 30 to 
50 ml of sterile physiologic saline. The saline was then aspirated, allowing recovery of 
cellular and non-cellular components of the epithelial surface of the lower respiratory 
tract
[64]
. 
Pleural fluid 
The pleural fluid was aspirated by thoracocentesis and collected in a sterile tube. 
Ascitic fluid 
Under strict aseptic precautions, ascitic fluid was collected and received  in a 
sterile test tube.  
Cerebrospinal fluid (CSF) 
Under sterile precautions lumbar puncture was done by the physician and CSF 
collected in a sterile test tube. 
 
Oral scrapings 
The oral lesions were scraped with a sterile cotton swab. 
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Nail 
Friable material was removed from under the nail or clippings were taken from 
the distal border using nail clippers
[49]
. 
Collection of swabs 
The wound surface was cleaned well with normal saline prior to the collection of 
swab.Two swabs were taken from the depth of the wound, one for Gram stain and 
another for culture. 
Blood 
Under strict aseptic precautions 5-10 ml blood was collected by venipuncture and 
inoculated into 50ml Brain heart infusion (BHI) broth immediately. 
Faeces 
Specimens were collected in clean wide mouthed containers. 
 
PROCESSING OF SAMPLES 
MACROSCOPIC EXAMINATION 
The samples were initially examined macroscopically as follows. 
 
TABLE II: MACROSCOPIC EXAMINATION 
Urine Observed for turbidity and color 
Sputum Examined whether the specimen is purulent, mucopurulent, 
mucoid, mucosalivary or blood stained 
Body fluids (ascitic fluid, 
CSF) 
Examined for turbidity, color, presence of blood or pus 
Faeces Looked for consistency, presence of mucus flakes, pus and 
blood 
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MICROSCOPIC EXAMINATION 
Direct microscopy 
The collected samples were subjected to the following direct microscopic examinations: 
a) Wet mount 
b) Gram staining 
c) Ziehl-Neelsen technique – for Acid Fast Bacilli (AFB) 
d) 10% potassium hydroxide mount (KOH) 
A drop of 10% KOH was added to a small amount of sample on the slide and 
mixed gently and covered with a coverslip. The preparation was examined after 
half an hour.  
e) India Ink preparation for CSF samples 
One drop of CSF was placed on a clean glass slide and mixed with a drop of India 
Ink and covered with a cover slip. The preparation was examined under low 
power objective for the presence of capsulated budding yeast cells. 
CULTURE 
Culture media 
Bacterial Culture: The samples were inoculated on MacConkey agar, Blood agar, and 
Chocolate agar and incubated at 37
0
C for 24 hours. Urine samples were inoculated on 
CLED and BAP. For faeces samples inoculation was also done in XLD. For suspected 
cases of Tuberculosis samples were also inoculated in LJ media. BHI broth and Selenite 
F broths were used as enrichment broths for blood and faeces samples respectively. 
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[BAP – Blood Agar Plate, CAP – Chocolate Agar Plate, LJ – Lowenstein Jensen media, 
MAC – MacConkey Agar, XLD – Xylose Lysine Deoxycholate media, CLED- Cysteine 
Lactose Electrolyte Deficient media.] 
Fungal Culture: Fungal culture was done in Sabouraud’s dextrose agar (SDA). 
 For isolating Mycobacterium tuberculosis, the samples were inoculated into 
two LJ slopes and incubated at 35
0
C - 37
0
C for 8 weeks. The slopes were 
examined daily for 1 week for any rapid growers and thereafter at weekly 
intervals for evidence of growth. 
 For fungal culture two SDA slopes were inoculated with the sample and one 
tube each were incubated at 25
0
C and 37
0
C. 
Processing of Urine samples  
A semi quantitative calibrated loop technique was used for the primary isolation 
of the organism from urine. A loopful of well mixed uncentrifuged urine was streaked 
onto the surface of blood agar and CLED (Cysteine Lactose Electrolyte Deficient) agar 
media and incubated at 37
0
C for 24 to 48 hrs. Significant bacteriuria was defined as the 
presence of 10
5
Colony Forming Units/ml (CFU/ml). The isolates were identified based 
on colony morphology on the culture plates, Gram staining, motility and by standard 
biochemical tests. 
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INTERPRETATION 
INTERPRETATION OF BACTERIAL CULTURES 
Bacterial isolates were identified by means of colony morphology, Gram staining, 
motility and biochemical reactions by standard microbiological techniques as 
recommended by Clinical and Laboratory Standards Institute (CLSI). 
INTERPRETATION OF FUNGAL CULTURE 
Inoculated SDA slants were incubated at 25
0
C and 35
0
C for a minimum of 4 
weeks before discarding as culture negative. These slants were inspected daily during the 
first week and twice weekly during the next three weeks for growth. 
Speciation of Candida 
The Candida isolates were speciated by Gram staining, Germ tube test, color of colonies 
on CHROMagar, and sugar fermentation reactions
[37]
. 
a) Germ Tube Test 
A single colony of Candida touched lightly with a loop and emulsified in 0.5 ml 
of serum in a test tube. Incubated at 37
0
C for 2- 4 hours. The germ tubes were seen as 
long tube like projections extending from the yeast cells
[49]
. 
b) Carbohydrate fermentation test 
1% yeast extract was added to the carbohydrate fermentation medium with 2% 
test sugars. The tubes were incubated at 30
0
 C for 24-48 hours. The results were usually 
obtained within 7 days
[41]
. 
c) CHROMagar Candida medium 
The Candida isolates were streaked in CHROMagar and incubated at 30
0
Cfor 48-
72 hours. Then colony morphology and color produced were observed. 
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Candida albicans- light green 
Candida dubliniensis- dark purple 
Candida glabrata- pink to purple 
Candida krusei- pink 
Candida parapsilosis- cream to pale pink 
Candida tropicalis- blue with pink halo 
 
ANTIMICROBIAL SUSCEPTIBILITY TESTING 
Antibiotic susceptibility testing was performed by the Kirby Bauer method on 
Mueller Hinton agar (Himedia) according to CLSI protocols. The diameters of zones of 
inhibition were interpreted according to CLSI standards for each organism. Using 
standard strains culture media and antibiotic discs were tested for quality control. 
The following standard strains were used. 
a) Staphylococcus aureus – ATCC 25923 
b) Escherichia coli – ATCC 25922 
c) Pseudomonas aeruginosa – ATCC 27853 
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The panel of antibiotics included in the antimicrobial sensitivity testing for Gram 
negative bacilli were as follows. 
 
TABLE III: ANTIMICROBIAL DISCS FOR GRAM NEGATIVE BACILLI 
 
Antimicrobial Disc content Inhibition Zone 
Resistant Intermediate Sensitive 
Amikacin 30 µg 14 15 – 16 17 
Gentamicin 10 µg 12 13 – 14 15 
Cotrimoxazole 1.25 / 23.75 µg 10 11 – 15 16 
Ofloxacin 5 µg 12 13 – 15 16 
Ciprofloxacin 5 µg 15 16 – 20 21 
Cefotaxime 30 µg 14 15 – 22 23 
Ceftazidime 30 µg 14 15 – 17 18 
Nitrofurantoin 300 µg 14 15 – 16 17 
Norfloxacin 10 µg 12 13 – 16 17 
Piperacellin / 
Tazobactum 
100 / 10 µg 17 18 – 20 21 
Imipenem 10 µg 13 14 – 15 16 
Ampicillin 10 µg 13 14 – 16 17 
Chloramphenicol 30 µg 12 13-17 18 
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The panel of antibiotics included in the antimicrobial sensitivity testing for Gram positive  
cocci were as follows. 
 
TABLE IV: ANTIMICROBIAL DISCS FOR GRAM POSITIVE COCCI 
Antimicrobial Disc content Inhibition Zone 
Resistant Intermediate Sensitive 
Amikacin 30 µg 14 15 – 16 17 
Erythromycin 15 µg 13 14 – 22 23 
Cotrimoxazole 1.25 / 23.75 µg 10 11 – 15 16 
Cephalexin 30 µg 14 15 - 17 18 
Ciprofloxacin 5 µg 15 16 – 20 21 
Amoxycillin / 
Clavulanic acid 
20 / 10 µg 19 - 20 
Penicillin 10 units 28 - 29 
 
Oxacillin (1 µg) disc was used to detect MRSA. Broth macrodilution method was 
done to obtain MIC for Vancomycin. MIC ≤ 2 µg / ml for vancomycin was reported as 
sensitive
[12]
. 
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A) DETECTION OF β LACTAMASE ENZYME PRODUCTION IN GRAM 
NEGATIVE BACILLI
[12]
 
 
1) SCREENING METHOD 
Isolate of gram negative bacilli with the following resistance pattern by disc diffusion 
method was considered to be possible ESBL producing strain. 
 
TABLE V: ZONE DIAMETER FOR ESBL PRODUCING STRAIN 
Antibiotic Zone diameter for possible ESBL 
producing strain 
Ceftazidime (30μg) ≤ 22mm 
Cefotaxime(30 μg) ≤ 27mm 
Ceftriaxone(30 μg) ≤ 25mm 
Aztreonam (30 μg) ≤ 27 mm 
 
2) CLSI PHENOTYPIC CONFIRMATION METHOD 
With a sterile bacteriological loop 3-5 identical colonies were picked from a fresh 
culture and inoculated into 5 ml of nutrient broth. The broth was incubated at 35°C for 2-
4 hrs. The turbidity was matched with 0.5 McFarlands standard. Lawn culture of the 
organism to be tested was made on MHA plate (Himedia, Mumbai). Antibiotic discs 
Ceftazidime (CAZ 30μg) and Ceftazidime/ Clavulanic acid (CAZ/ CA 30μg/ 10μg) 
(Himedia, Mumbai) were placed on the plate and incubated at 35°C overnight. Organism 
with ≥5mm increase in zone diameter for Ceftazidime tested in combination with 
Clavulanic acid versus its zone when tested alone confirms an ESBL producing 
organism. 
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3) DOUBLE DISK DIFFUSION SYNERGY TEST 
In this test discs of third generation cephalosporins (ceftazidime and cefotaxime) and 
Augmentin (20μg/10μg) (Himedia, Mumbai) were kept 30 mm apart from center to 
center on inoculated Muller-Hinton Agar (MHA). The test organism was considered to be 
an ESBL producer, if the zone size around the cephalosporin disc increases towards the 
augmentin disc. 
 
4) TRIPLE ESBL DETECTION USING EZY MICTM STRIP (HIMEDIA) 
The organism to be tested was swabbed onto a Muller-Hinton Agar (MHA) plate. Ezy 
MIC
TM
 strip was placed on the inoculated agar plate and incubated at 37
0
C overnight. 
MIC was interpreted as the point of intersection of the inhibition ellipse with E Test strip 
edge. Ratio of Cephalosporin MIC and Cephalosporin Clavulanic acid MIC ≥ 8 indicates 
positive result. 
 
B) DETECTION OF METHICILLIN RESISTANCE IN Staphyloccus aures 
1) DISC DIFFUSION METHOD 
A lawn culture of the Staphylococcal culture was made on the MHA plate and 
Oxacillin disc was applied and incubatedat 35° C for 24 hours in ambient air. According 
to CLSI criteria with 1μg Oxacillin disc, diameters of ≤ 10, 11-12, ≥ 13 mm 
corresponded to categorization as resistant, intermediate or susceptible
[12]
. 
2) OXACILLIN SCREEN AGAR 
Oxacillin screen agar was performed by direct colony suspension method. The 
inoculum was adjusted to match a turbidity of 0.5 McFarland standard. Then the 
44 
 
suspension was inoculated on Mueller-Hinton agar plate containing 4% NaCl and with 
6μg/ml of Oxacillin and incubated at 35°C for 24 hours. If growth was seen on the plates, 
the organism was considered as methicillin resistant. 
 
C) MINIMUM INHIBITORY CONCENTRATION (MIC) FOR DETECTING 
VANCOMYCIN RESISTANCE 
 
 Culture media used 
Mueller Hinton broth. (pH 7.2-7.4) 
 
 Preparation of stock antibiotic solution 
Antibiotic stock solution was prepared using the formula 
W = 
    
 
         
where 
p=potency of the antibiotic in relation to the base. (For vancomycin, p= 950/1000 mg; 
Himedia) 
V = volume of the stock solution to be prepared (10ml) 
C =final concentration of the antibiotic solution (1024μg/ml) 
W = weight of the antibiotic to be dissolved in the volume V 
 
 Antibiotic dilutions were prepared from concentration of 32µg/ml to 0.125µg/ml. 
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 Inoculum preparation for the test organism and ATCC control and 
incubation 
 To 9.9 ml of MH broth 0.1 ml of 0.5 McFarland turbidity matched test 
organism broth was added and mixed well. 
 1 ml of this inoculum was transferred to each tube containing antibiotic 
dilutions and also to the control tube. 
 The procedure was repeated for ATCC control strains 
 Incubated at 370C overnight and then reading was taken. 
 The lowest concentration of the antibiotic at which there is no visible 
growth will be the MIC for the test organism. 
 
ANTIFUNGAL SUSCEPTIBILITY TESTING BY MICRODILUTION METHOD 
Antifungal susceptibility testing was done according to the CLSI M-38A 
document for filamentous fungi and CLSI M-27A2 document for yeast. 
PROCEDURE 
GROWTH MEDIUM 
The growth medium used was RPMI-1640 (Rosewell Park Memorial Institute-
1640) which is a synthetic medium and is supplemented with 0.3 l-glutamate/L without 
sodium bicarbonate. It is buffered at the pH of 7.0- 7.2 using MOPS(3-N-
morpholinopropane sulfonic acid). 
DRUG DILUTION PREPARATION 
The drug dilutions were prepared as described in the CLSI M38-A document. 
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INOCULATION IN RPMI-1640 MEDIUM AND INTERPRETATION 
The inoculation was done in sterile 96-well microtitre plate. 100µl of the conidial 
suspension/ yeast suspension was inoculated into each well. Then 100µl of diluted drug 
was added correspondingly to each well. Controls were also inoculated and microtitre 
plates were incubated at 35
0
C for 48 hours and then reading was taken. The growth in 
each well was compared with that of the growth control with a reading mirror. A 
numerical score is given to each well as follows: 
 4 – no reduction in growth 
 3 – slight reduction in growth or 75% of growth control 
 2 – prominent reduction in growth or 50% of growth control 
1 – slight growth or 25% of growth control 
0 – optically clear or absence of growth 
 
ANTINUCLEAR ANTIBODY (ANA) DETECTION BY INDIRECT 
IMMUNOFLOURESCENCE METHOD 
 
The Kit usedis: HEp-2 slides (Biocientifica S.A) 
PROCEDURE 
a) The serum samples were diluted as 1:10 and 1:40 
b) The diluted samples and controls were added to the slides to cover the reactive areas. 
c) Incubated in a moist chamber for 30 minutes at room temperature. 
d) The slides were washed three times in a trough containing Phosphate Buffered Saline 
(PBS) and wiped with filter paper keeping the reactive areas wet. 
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e) Each reactive area covered immediately with diluted human Anti-IgG FITC and 
incubated in a moist chamber for 30 min at room temperature. 
f) Step 4 was repeated. 
g) The reactive areas were covered with Evan’s blue and the excess stain washed with 
PBS, wiped with filter paper. 
h) The mounting fluid added immediately and examined under immunoflourescence 
microscope. 
DETECTION OF ANTIBODIES TO ds DNA BY IgG ELISA 
(The Calbiotech, Inc. (CBI) ds DNA IgG ELISA Kit) 
a) 10 μl of the sample added to 200 μl of sample diluent to prepare 1:21 dilution. 
b) 100 μl of diluted sera, calibrator and controls were dispensed into the appropriate 
wells. Incubated for 20 minutes at room temperature. 
c) The liquids were removed from all wells and washed three times with 300 μl of 1X 
wash buffer and blotted on absorbance paper. 
d) 100 μl of enzyme conjugate dispensed to each well and incubation done for 20 
minutes at room temperature. 
e) Enzyme conjugate was removed from all wells. Washed the wells three times with 
300 μl of 1X wash buffer and blotted on absorbance paper. 
f) Dispensed 100 μl of TMB substrate and incubated for 10 minutes at room 
temperature. 
g) Added 100 μl of stop solution. 
h) O.D. read at 450 nm using ELISA reader within 15 min. 
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STUDY OF COMPLEMENT LEVELS (C3 and C4) 
The kit used is Diffu-Plate (Biocientifica S.A) 
This kit is used for measurement of human C3 and C4 levels in serum and other 
biological fluids. It uses the principle of radial immunodiffusion (RID) and involves 
diffusion of antigen radially from a cylindrical well through an agarose gel which 
contains the appropriate  monospecific antibody. Antigen antibody complexes are formed 
which will form a precipitin ring. Serum samples from all SLE patients were subjected to 
quantitative analysis of Complement levels by the following procedure. 
EQUIPMENTS REQUIRED 
1) RID plate for 12 tests packed in foil pouch 
2) Micropipettes 
3) Control sera 
4) Ruler capable of measuring with 0.1 mm precision 
5) Reference table showing the correspondence between diameters and 
concentrations 
PROCEDURE 
1) The RID plates were opened and kept at room temperature for 5 minutes. 
2) Wells were filled with 5 µl of test serum or control serum. A wet gauze was 
placed in the center of the plate to avoid agarose dehydration and plates were 
closed tightly. 
3) The plates were allowed to stay flat at room temperature for 48 hours. 
4) The ring diameters were measured at the end of incubation. 
5) The results were read from the RID reference table. 
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RESULTS 
A total of 110 SLE patients with clinically suspected infections were studied.  
TABLE 1: AGE-SEX DISTRIBUTION OF SLE PATIENTS 
n=110 
Gender → Male Female Total 
Age Range ↓ No. Percentage No. Percentage No. Percentage 
0 – 10(n=1) 1 100.00% 0 0.00% 1 0.91% 
11 – 20(n=28) 3 10.71% 25 89.29% 28 25.45% 
21 – 30(n=58) 4 6.90% 54 93.10% 58 52.73% 
31 – 40(n=17) 3 17.65% 14 82.35% 17 15.45% 
41 – 50(n=5) 1 20.00% 4 80.00% 5 4.55% 
51 – 60(n=1) 0 0.00% 1 100.00% 1 0.91% 
Total 12 10.91% 98 89.09% 110 100.00% 
 
 Out of 110 SLE patients included in the present study 98 were female and 12 
were male. There was a female preponderance with a female:male ratio of 8:1.  
 52.73 % of the patients were in the age group of 21 to 30 years.  
 The mean age of male and female SLE patients were 24.83 and 25.68 
respectively. 
 The mean age at diagnosis of male and female SLE patients were 24.83 and 25.68 
respectively. 
 The average duration of SLE was 37 months (3.08 years). 
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TABLE 2: CHILDHOOD SLE 
n = 15 
Gender No. Percentage 
Male 2 13.33% 
Female 13 86.67% 
Total 15 
  
Among the 110 SLE patients, 15 patients (13.6%) were children. Mean age of onset of 
disease in childhood lupus was 13 years and female:male ratio was 6.5:1 
 
TABLE 3: FREQUENCY OF VARIOUS CLINICAL MANIFESTATIONS IN SLE 
PATIENTS 
n=110 
Clinical Manifestations Number Percentage 
Arthritis 73 66.36% 
Fever 54 49.09% 
Skin rash 49 44.55% 
Anaemia 48 43.64% 
Oral ulcers 46 41.82% 
Renal involvement 45 40.91% 
Alopecia 31 28.18% 
Malar rash 30 27.27% 
Neuropsychiatric Manifestation 28 25.45% 
Photosensitivity 27 24.55% 
Cardiovascular Involvement 9 8.18% 
Past History of Tuberculosis 8 7.27% 
Antiphospholipid antibody syndrome 7 6.36% 
Hypothyroidism 5 4.55% 
Pleural effusion 5 4.55% 
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Arthritis was the common clinical manifestation seen in 73 (66.36%) patients followed 
by fever 54 (49.09%), skin rash 49 (44.55%) and anaemia 48 (43.64%). 
 
TABLE 4: DISTRIBUTION OF PATIENTS WITH LUPUS NEPHRITIS (LN) 
n = 45 
Patients →→→ 
No. Percentage Lupus Nephritis Class   ↓ 
Lupus Nephritis - Class I 
(n=6) 6 13.33% 
Lupus Nephritis - Class II 
(n=10) 10 22.22% 
Lupus Nephritis - Class III 
(n=7) 7 15.56% 
Lupus Nephritis - Class IV 
(n=19) 19 42.22% 
Lupus Nephritis - Class V 
(n=3) 3 6.67% 
Total 45   
 
 Among the 110 SLE patients, 45 patients had renal involvement in the form of 
Lupus Nephritis.  
 The most common class of Lupus Nephritis (LN) was Class 4 (42.22%) followed 
by Class 2 LN (22.22%).  
 The frequencies of other LN classes were LN Class 3 (15.56%), LN Class 1 
(13.33 %) and LN Class 5 (6.67%). 
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TABLE 5: ANALYSIS OF DISTRIBUTION OF COLLECTED SAMPLES 
n=150 
  Samples Collected 
Type of sample ↓ No. Percentage 
Urine 84 56.00% 
Sputum 22 14.67% 
Blood 21 14.00% 
Pus 8 5.33% 
Ear Swab 2 1.33% 
Oral scrapings 2 1.33% 
Ascitic fluid 1 0.67% 
BAL 1 0.67% 
Nail scraping 1 0.67% 
CSF 3 2.00% 
Faeces 5 3.33% 
Total 150 100.00% 
 
From the 110 SLE patients the main samples collected were urine 84 (56%), sputum 22 
(14.67%) and blood 21 (14%). The rest of the samples are mentioned in the above tabular 
column. 
 
TABLE 6: FREQUENCY OF PATIENTS WITH AND WITHOUT INFECTION 
n=110 
Patients distribution   ↓↓↓ No. Percentage 
No. of Patients with Infection 60 54.55% 
No. of Patients without Infection 50 45.45% 
Total 110 100.00 % 
 
Among the 110 SLE patients, 60 (54.55%) had infectious episodes.  
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TABLE 7: GENDER DISTRIBUTION OF PATIENTS WITH AND WITHOUT 
INFECTION 
n=110 
Gender   →→→ Male Female 
Patients   ↓↓↓ No. Percentage No. Percentage 
Patients with infection 
(n=60) 7 11.67% 53 88.33% 
Patients without infection 
(n=50) 5 10.00% 45 90.00% 
 
Out of 110 SLE patients, 60 patients had infection. Among them 53 were female and 7 
were male. Out of the 60 patients with infection, 3 died due to infections like pneumonia 
and sepsis. 
 
TABLE 8: EPISODES OF INFECTION IN SLE PATIENTS 
n=60 
Number of 
episodes 
One Two Three 
No. of Patients 51 8 1 
 
 Among the 60 patients with infection, 51 patients had one episode of infection whereas 8 
patients had 2 episodes and 1 patient had 3 episodes of infection. 
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TABLE 9: DISTRIBUTION OF SAMPLES WITH SIGNIFICANT GROWTH 
n=74 
Sites Of Infection Significant growth 
  No. Percentage 
Urinary Tract 40 54.05% 
Respiratory Tract (Sputum/BAL) 12 16.22% 
Blood 9 12.16% 
Skin and Soft Tissue(Pus, nail scraping) 8 10.81% 
Ear 2 2.70% 
Oral Cavity 2 2.70% 
Peritoneum 1 1.35% 
Total 74 
  
Out of 150 samples collected, significant growth was found in 74 samples. 
Infections were common in urinary tract (54.05%). Next significant growth was found in 
respiratory tract 12 (16.22%). Other sites of infection were mentioned in the above table 
in the decreasing order of frequency. No significant growth was obtained from samples of 
CSF and faeces. 
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TABLE 10: DISTRIBUTION OF ISOLATED ORGANISMS 
Bacterial Isolates 
Bacteria Isolated Number 
Escherichia coli 20 
Pseudomonas aeruginosa 14 
Klebsiella pneumoniae 12 
Staphylococcus aureus 10 
Staphylococcus epidermidis 3 
Acinetobacter baumannii 2 
Enterococcus faecalis 2 
Proteus mirabilis 2 
Citrobacter freundii 1 
Klebsiella oxytoca 1 
Salmonella typhi 1 
Total 68 
 
Fungal Isolates 
Fungi Isolated Number 
Candida albicans 4 
Candida tropicalis 1 
Aspergillus flavus 1 
Total 6 
 
Bacterial infections were predominant than fungal infections in patients with SLE. 
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TABLE 11: DISTRIBUTION OF ORGANISMS ISOLATED FROM URINARY 
TRACT 
n=40 
Organism Isolated Number Percentage 
Gram Negative Bacteria 
Escherichia coli 20 50.00 
Pseudomonas aeruginosa 4 10.00 
Klebsiella pneumoniae 2 5.00 
Proteus mirabilis 2 5.00 
Citrobacter freundii 1 2.50 
Klebsiellaoxytoca 1 2.50 
Acinetobacter baumannii 1 2.50 
Gram Positive Bacteria 
Staphylococcus aureus 4 10.00 
Enterococcus faecalis 2 5.00 
Staphylococcus epidermidis 1 2.50 
Yeast 
Candida albicans 1 2.50 
Candida tropicalis 1 2.50 
Total 40 
  
Out of 84 urine samples processed significant growth was present in 40 samples. 
Escherichia coli was the predominant Gram negative bacteria isolated from 20 (50%) 
samples. Among Gram positive bacteria, Staphylococcus aureus was the common isolate 
from 4 (10%) patients. 
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TABLE 12: DISTRIBUTION OF ORGANSISMS ISOLATED FROM 
RESPIRATORY TRACT 
n=12 
Organism Isolated Number Percentage 
Gram Negative Bacteria 
Klebsiella pneumoniae 8 66.67% 
Pseudomonas aeruginosa 2 16.67% 
Gram Positive Bacteria 
Staphylococcus aureus 1 8.33% 
Staphylococcus epidermidis 1 8.33% 
Total 12   
 
A total of 23 samples were processed from respiratory tract, out of which 12 samples 
showed significant growth.  
Klebsiella pneumoniae was the predominant organism isolated from 8 (66.67%) patients. 
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TABLE 13: DISTRIBUTION OF ORGANISMS ISOLATED FROM BLOOD 
n=9 
Organism Isolated Number Percentage 
Gram Negative Bacteria 
Klebsiella pneumoniae 2 22.22% 
Pseudomonas aeruginosa 2 22.22% 
Salmonella typhi 1 11.11% 
Acinetobacter baumannii 1 11.11% 
Gram Positive Bacteria 
Staphylococcus aureus 2 22.22% 
Staphylococcus epidermidis 1 11.11% 
Total 9 
 
 
A total of 9 organisms were isolated from 21 samples of blood processed. Out of 
the 6 Gram negative bacteria isolated, Klebsiella pneumonia and Pseudomonas 
aeruginosa constituted (2 patients) 22.22% each. Among Gram positive bacteria, 
Staphylococcus aureus was the predominant isolate. 
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TABLE 14: DISTRIBUTION OF ORGANISMS ISOLATED FROM SKIN AND 
SOFT TISSUE 
n = 8  
 
No. of 
Organisms Percentage 
Pseudomonas aeruginosa 4 50.00% 
Staphylococcus aureus 3 37.50% 
Candida albicans 1 12.50% 
Total 8 
  
Among the 9 samples processed (pus-8, oral scraping-1) 8 organisms were isolated from 
infections of skin and soft tissue. Out of which Pseudomonas aeruginosa constituted 
50%, followed by Staphylococcus aureus 37.5% and Candida albicans 12.5%. 
 
TABLE 15: DISTRIBUTION OF ORGANISMS ISOLATED FROM OTHER 
SITES 
Organism / 
System 
Pseudomonas 
aeruginosa 
Candida 
albicans Aspergillusflavus 
Ear 1 - 1 
Oral Cavity - 2 - 
Peritoneum 1 - - 
 
a) Aspergillus flavus and Pseudomonas aeruginosa one each were isolated from ear 
infection. 
b) Candida albicans was isolated from oral cavity of 2 patients with oral thrush. 
c) Pseudomonas aeruginosa was the causative agent of peritonitis in one patient 
with SLE. 
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TABLE 16: ANALYSIS OF VARIOUS SITES OF INFECTIONS IN PATIENTS 
WITH LUPUS NEPHRITIS 
 
 
n=45 
Patients →→→ Infected Not Infected 
Lupus Nephritis Class   ↓ No. % No. % 
Lupus Nephritis - Class I 
(n=6) 0 0.00% 6 100.00% 
Lupus Nephritis - Class II 
(n=10) 8 80.00% 2 20.00% 
Lupus Nephritis - Class III 
(n=7) 2 28.57% 5 71.43% 
Lupus Nephritis - Class IV 
(n=19) 15 78.95% 4 21.05% 
Lupus Nephritis - Class V 
(n=3) 2 66.67% 1 33.33% 
 
 Among the 45 patients with LN, infections were present in 27 (60%)  patients and 
Urinary tract was the common site of infection involved in 17 (62.96%) patients. 
 Out of the 45 SLE patients with LN, 6 patients were on haemodialysis. 
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TABLE 17: FREQUENCY OF SITES INVOLVED IN VARIOUS CLASSES OF 
LUPUS NEPHRITIS 
 
 
n=27 
 
 
 Out of 27 Lupus Nephritis patients with infection, 17 (62.96%) patients had 
urinary tract infection. 
 
 The other less frequently involved sites in Lupus Nephritis patients were blood, 
respiratory tract, skin and soft tissue, and peritoneum. 
 
 The sites of infection are similar in patients with and without lupus nephritis. 
 
  
62 
 
TABLE 18: ANTIBACTERIAL SUSCEPTIBILITY PATTERN OF GRAM 
NEGATIVE BACTERIA FROM URINARY TRACT 
 
n=31 
 
 
[AK – Amikacin; GENTA – Gentamicin; COTRI – Cotrimoxazole; CEF – Cefotaxime;  
CZ – Ceftazidime; PT – Piperacillin / Tazobactum; FU – Nitrofurantoin; NF – Norfloxacin; IMI –
Imipenem] 
 
 
 The organisms showed resistance pattern to wide range of antibiotics like 
Cotrimoxazole, Nitrofurantoin, Norfloxacin and third generation Cephalosporins. 
 
 All the gram negative bacteria isolated from urinary tract were 100% sensitive to 
Imipenem. 
  
63 
 
TABLE 19: ANTIBACTERIAL SUSCEPTIBILITY PATTERN OF GRAM 
NEGATIVE BACTERIA FROM SITES OTHER THAN URINARY TRACT 
 
n=21 
 
 
[AK – Amikacin; GENTA – Gentamicin; CIP - Ciprofloxacin; OF – Ofloxacin;  
CEF – Cefotaxime; CZ – Ceftazidime; PT – Piperacillin / Tazbactum; IMI –Imipenem] 
 
 A total of 21 Gram Negative Bacteria were isolated from various sites like 
respiratory tract, blood, skin and soft tissue, ear and peritoneum. 
 
 The organisms showed significant resistance to Cephalosporins and 
Fluoroquinolones. 
 
 One isolate of Salmonella typhi was found sensitive to all the antibiotics tested 
like Ampicillin, Ciprofloxacin, Gentamicin, Cotrimoxazole, Chloramphenicol and 
Ceftazidime. 
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TABLE 20: ANTIBACTERIAL SUSCEPTIBILITY PATTERN OF GRAM 
POSITIVE COCCI FROM URINARY TRACT 
n=6 
 
 
[AK – Amikacin; COTRI – Cotrimoxazole; ERY – Erythromycin, CIP – Ciprofloxacin;  
CEP – Cephalexin; AC – AmoxycillinClavulanate; VAN – Vancomycin] 
 All the six gram positive cocci from urinary tract were sensitive to Vancomycin 
by MIC method. ( MIC < 2 µg/ml) 
 
TABLE 21: ANTIBACTERIAL SUSCEPTIBILITY PATTERN OF GRAM 
POSITIVE COCCIFROM SITES OTHER THAN URINARY TRACT 
n=8 
 
 
[AK – Amikacin; COTRI – Cotrimoxazole; ERY – Erythromycin, CIP – Ciprofloxacin;  
CEP – Cephalexin; PEN – Penicillin; AC – AmoxycillinClavulanate; VAN – 
Vancomycin] 
 
 A total of eight gram positive cocci were isolated from various sites like blood, 
respiratory tract, and skin and soft tissue. 
 All of them were found sensitive to Vancomycin by MIC. (MIC < 2µg/ml) 
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TABLE 22: DISTRIBUTION OF ESBL PRODUCING ORGANISMS 
 
Organism No. Percentage 
Escherichia coli (n=20) 15 75.00% 
Pseudomonas aeruginosa (n=14) 9 64.29% 
Klebsiella pneumoniae (n=12) 4 33.33% 
Citrobacter freundii (n=1) 1 100.00% 
Klebsiella oxytoca (n=1) 1 100.00% 
 
 
 Out of the 53 gram negative bacteria isolated, 30 were ESBL producers. 
 Escherichia coli was the predominant ESBL producer. (15 out of 20) 
 
TABLE 23: DETECTION OF MRSA AMONG THE ISOLATES OF 
Staphylococcus aureus 
n=10 
Organism Disc diffusion method Oxacillin salt agar 
Staphylococcus aureus 8 (100 %) 8 (100 %) 
 
 Among the ten isolates of Staphylococcus aureus,8 were found to be MRSA by 
both disc diffusion method and Oxacillin salt agar method. 
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TABLE 24: ANTIFUNGAL SUSCEPTIBILITY OF FUNGI BY BROTH 
MICRODILUTION METHOD 
 
Drugs   →→→ AMB ITRA FLU VORI 
Organisms   ↓↓↓     
Candida albicans 
(n=4) 
S S S S 
Candida tropicalis 
(n=1) 
S S S S 
Aspergillus flavus 
(n=1) 
S S - S 
 
AMB – Amphotericin B; ITRA – Itraconazole; FLU – Fluconazole; VORI - 
Voriconazole 
All the fungi isolated were sensitive to the antifungals tested by broth microdilution 
method. 
The MIC of AMB, ITRA, VORI for Candida spp. was ≤ 1 µg/ml and ≤ 8 µg/ml for FLU. 
The MIC of AMB was ≤ 2 µg/ml and ≤ 8 µg/ml for ITRA and VORI when testing for 
Aspergillus flavus. 
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TABLE 25: ANALYSIS OF IMMUNOLOGICAL PARAMETERS IN SLE 
PATIENTS 
n= 110 
 
Immunological Parameters 
No. of 
patients Percentage 
Positive ANA 108 98.18% 
Positive Anti-ds DNA 77 70.00% 
Both ANA and Anti-ds DNA Positive 77 70.00% 
 
Among 110 SLE patients, ANA was positive in 108 (98.18 %) patients and Anti-ds DNA 
was positive in 77 (70%) patients. 77 patients with positive Anti-ds DNA were also 
positive for ANA. 
 
TABLE 26: ANALYSIS OF ANA PATTERNS IN SLE PATIENTS BY INDIRECT 
IMMUNOFLOURESCENCE 
n= 108 
 
ANA Patterns No. Percentage 
Homogenous 56 51.85% 
Speckled 28 25.93% 
Rim 24 22.22% 
Total 108 
  
The ANA patterns were studied using Hep-2 slides by Indirect Immunoflourescence 
method. Homogenous pattern was the common pattern  present in 56 (51.85%) patients 
followed by Speckled pattern and Rim pattern. 
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TABLE 27: ANALYSIS OF C3 / C4 LEVELS IN SLE PATIENTS 
 
n= 110 
 
C3 / C4 No. Percentage 
Low C3 70 63.64% 
Low C4 61 55.45% 
Low C3 and C4 60 54.55% 
 
Normal values of C3 and C4 
C3: 80- 160 mg/dl 
C4: 20- 40 mg/ dl 
 
 By RID method C3 and C4 levels were analyzed in 110 SLE patients and it was 
found that C3 Levels were decreased in 70 (63.64%) patients and C4 levels were 
decreased in 61 (55.45%) patients.  
 
 Both C3 and C4 levels were decreased in 60 (54.55%) patients. 
 
 
 
  
69 
 
TABLE 28: STEROID VS. INFECTION 
n = 110 
  
Total no. 
of patients Infected Not Infected 
Daily Prednisolone  
dosage ↓   No. % No. % 
< 20 mg 74 31 41.89% 43 58.11% 
≥ 20 mg 36 29 80.56% 7 19.44% 
Total 110 60   50   
 
Daily Prednisolone dosage ≥ 20 mg was associated with an increased risk of infection 
with a p value 0.0003. (<0.05 which is statistically significant) 
 
TABLE 29: CYCLOPHOSPHAMIDE + STEROID VS. INFECTION 
n = 110 
    Infected Not Infected 
  
Total no. of 
patients No. % No. % 
No. of patients on  
Cyclophosphamide + 
Prednisolone 29 22 75.86% 7 24.14% 
No. of patients not on  
Cyclophosphamide 81 39 48.15% 42 51.85% 
Total 110 61   49   
 
The risk of infection was higher in patients receiving Cyclophosphamide + Prednisolone 
with a p value of 0.0183 (p value <0.05 which is statistically significant) 
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TABLE 30: MMF VS. INFECTION 
 
n=110 
 
    Infected Not Infected 
  
Total no. of  
patients No. % No. % 
No. of patients on  
Mycophenolatemofetil 8 4 50.00% 4 50.00% 
No. of patients not on  
Mycophenolatemofetil 102 57 55.88% 45 44.12% 
Total 110 61 
 
49 
  
 Out of the 110 SLE patients included in this study, only 8 were on treatment with 
MMF.  
 
 Among the 8 patients on MMF, only 4 developed infectious episodes. 
 
 No association was found between MMF intake and infection with a p value of 
0.7472 (p value > 0.05 which is statistically not significant). 
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DISCUSSION 
SLE is a systemic autoimmune disease mainly affecting women of reproductive 
age group. Due to the various immunological dysfunctions, SLEpatients are inherently at 
risk for infections. This susceptibility to infections is further increased by the 
immunosuppressants which are used in the treatment of SLE. 
This study was conducted at the Institute of Microbiology, Madras Medical 
College in association with the Departments of Rheumatology and Nephrology, Rajiv 
Gandhi Government General Hospital, Chennai, to detect the bacterial and fungal 
pathogens causing infection in SLE patients. This study also focused on the various 
clinical manifestations, immunological parameters and association of infection with 
steroids and other immunosuppressants. 
Among the 110 SLE patients included in the study there were 98 female and 12 
male. The female:male ratio of SLE patients in the present study was 8:1 [TABLE:1]. 
This female preponderance highlights the role played by sex hormones on the 
development of SLE. Malaviya et al
[54]
in their study reported a female to male ratio of 
8:1. Jacobsen, Petersen et al, in a Danish study conducted at Copenhagen on 513 patients 
also showed a similar female to male ratio of 8:1
[35]. 
The female to male ratio in a 
multicenter study conducted by Cervera, Khamashta et al.
[76]
 over a 5 year period is 10:1. 
H-AL-Rayes et al.
[26]
in their study showed a lower female to male ratio of 4.4:1. 
In this study the median age of onset of SLE was 22 years. Binoy et al
[69]
observed 
a median age of disease onset at 21.6 years which is in agreement with the present study. 
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Malaviya et al.
[54]
 and Vaidya et al
[85]
have noted a median age of disease onset of 24 and 
26 years respectively. This is higher than the age of disease onset of the present study. 
Duration of SLE ranged from one month to 19 years with a mean of 37 months. In 
a study done in Western India on 60 SLE patients, Renu Saigal et al
[73]
noted a mean 
duration of SLE as 24 months. Malaviya et al
[54]
reported median duration of SLE as 17 
months. Both the studies show a lower age of disease onset compared with the present 
study.   
Most of the patients (52.73%) were in the reproductive age group of 21 to 30 
years. This is in agreement with the study by Renu Saigal et al
[73]
 in which majority of 
patients were in the age group of 21 to 30 years. 
In this study of 110 SLE patients, 15 (13.6%) patients were children (aged below 
16 years) which is lower than the earlier reports indicating 15-17% of all SLE patients are 
children worldwide
[18] 
[TABLE:2].  The mean age of onset of disease in childhood lupus 
in the present study was 13 years. Huang et al
[40]
 in their study on Paediatric lupus also 
observed a mean age at diagnosis of 8.6-13.5 years which is comparable to the current 
study. The female to male ratio in the childhood lupus group in the current study was 
6.5:1. Huang et al (D 9) also reported a female to male ratio of 6.2:1 in children with 
SLE. 
The common clinical manifestations observed in the study group were arthritis 
(66.36%), fever (49.09%) and skin rash (44.55%)[TABLE:3] which is in agreement with 
the study done by Kosaraju et al.
[44]
 in South Indian SLE patients. The other clinical 
manifestations observed in the study were anaemia (43.64%), oral ulcers (41.82%), renal 
73 
 
involvement (40.91%), alopecia (28.18%), malar rash (27.27%), neuropsychiatric 
manifestations (25.45%) and photosensitivity (24.55%). In reports given by Malaviya et 
al.
[54]
 and Alarcon et al. 
[70]
renal involvement, malar rash, oral ulcers, neuropsychiatric 
manifestations and photosensitivity were the common clinical manifestations.  
The other associated illnesses in the present study include cardiovascular 
involvement (9), hypothyroidism (5), pleural effusion (5), history of tuberculosis (8), 
APS (7), history of abortion (3), retinal vasculitis (2) and avascular necrosis of bone (2). 
Two patients gave family history of SLE, out of them mother of one patient had 
SLE. Another patient had two sisters with SLE, of which one of them died due to SLE 
related complications. In a study of clinical profile of SLE patients in Western India by 
Renu Saigal et al.
[73]
 family history of SLE was present in 4 patients. 
Among the 110 patients included in the study, 45 patients (40.91%) had lupus 
nephritis[TABLE:4]. This is comparable to the study of Madhavan et al. 
[50]
involving 54 
SLE patients in which renal involvement has been recorded in 38.8% of patients.  
In this study, WHO class IV nephritis was the most commonly seen histological 
pattern seen in 19 (42.22%) patients and this finding is comparable to the following two 
studies. In a study conducted by Renu Saigal et al. 
[73]
 on 60 SLE patients, class IV LN 
was the common histologic pattern observed. Similarly a study by C.C.Mok et al. (D29) 
also recorded LN class IV in 65 % of patients with LN.  
The samples collected from SLE patients include urine, sputum, blood, nail 
scrapings, ear swab, oral scrapings, ascitic fluid, cerebrospinal fluid and 
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faeces[TABLE:5]. In this study of 110 SLE patients, 60 (54.55%) patients suffered from 
infection. de Luis et al.
[14]
in their study which included 96 cases of SLE reported 
infection in 55% of patients, H-Al-Rayes et al.
[26]
in their retrospective study of 199 SLE 
patients in Saudi Arabia recorded infection in 58.79% of patients and the present study is 
comparable with both  the above studies. 
A total of 74 infections were observed in 60 patients in this study, 
[TABLE:6,7]out of which 51 patients experienced one infectious episode, 8 had two 
episodes of infection and 1 patient had 3 episodes of infection.[TABLE:8] In 4 patients 
with single episode of infection, two sites were involved.  
The most common sites of infection were the urinary tract and the respiratory 
tract which contributed to 54.05% and 16.22% of all the infections 
respectively[TABLE:9]. This preponderance of urinary and respiratory tract has also 
been observed in other studies conducted by Ginzler E et al. 
[21]
, Staples PJ et al. 
[79]
and 
de Luis et al. 
[14]
 
Other sites involved in the present study were blood (12.16%), skin and soft tissue 
(10.81%), ear (2.7%), oral cavity (2.7%) and peritoneum (1.35%). de Luis et al. 
[14]
 
reported skin and soft tissue and blood as the third and fourth common sites of infection.  
In this study, bacterial infections 93.24% (69 out of 74) were common than fungal 
infections[TABLE:10]. This is in agreement with earlier reports of upto 80% incidence 
of bacterial infections in SLE patients from India 
[78]
, Malaysia 
[68]
, Singapore 
[66]
, 
Spain
[14]
 and United States of America 
[65]
.  
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Most frequently isolated uropathogen was Escherichia coli(50%) [TABLE:11], a 
result which is similar to that described by C Hidalgo-Tenorio et al. 
[91]
in their study in 
Spain. The other pathogens responsible for urinary tract infection were Pseudomonas 
aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Klebsiella pneumoniae, 
Proteus mirabilis, Citrobacter freundii, Klebsiella oxytoca, Staphylococcus epidermidis, 
Acinetobacter baumannii, Candida albicans and Candida tropicalis. 
Klebsiella pneumoniae was the frequently isolated organism from respiratory 
tract.[TABLE:12].The other less frequently isolated organisms were Pseudomonas 
aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis. 
In this study, 9 (12.16%) patients had one episode of bacteremia and the leading 
cause of gram positive bacteremia was Staphylococcus aureus and gram negative 
bacteremia was Klebsiella pneumoniae and Pseudomonas aeruginosa.[TABLE:13]. 
Chen et al
[58]
in their study documented bacteremia in 17% of SLE patients. The result of 
the present study is lower than the above study. Salmonella bacteremia was present in 
one patient. An increased association of Salmanellosis has been reported in SLE patients 
by Reyes et al. 
[75]
. 
Pseudomonas aeruginosa was the common isolate from skin and soft tissue 
followed by Staphylococcus aureus and Candida albicans[TABLE:14].The other less 
frequently involved sites are ear, oral cavity and peritoneum [TABLE:15]. 
Tuberculosis is an important cause of morbidity and mortality in patients with 
SLE especially in endemic countries like India. In the present study, 8 patients had 
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history of tuberculosis. In a study done in South Indian SLE patients by Kosaraju et al
[44]
, 
history of tuberculosis has been reported in 6 patients. 
Fungus was isolated from 6 patients and accounted for 8.1 % (6 out of 74) of 
infections [TABLE:10]. Candida was the most common fungus isolated. Candida 
albicans was isolated from oral scrapings of two patients who presented with oral thrush, 
one patient with fungal infection of nail and one patient with Urinary tract infection 
(UTI). Candida tropicalis was isolated from one patient with UTI. This is in agreement 
with Ginzler et al.
[21]
 who observed that Candida infection is the common fungal 
infection in patients with SLE most often presenting with oral thrush. In a study done by 
H-Al-Rayes et al.
[26]
Candida albicans is the most common fungus associated with 
infections in SLE patients.  
Aspergillus flavus was isolated from a case of SLE with ear infection.  Ruiz 
Irastorza et al
[25]
 reported a case of Aspergillus infection in their study in 83 patients with 
SLE. 
Urinary tract was the most common site involved in patients with LN accounting 
for 62.96% of infections in them.[TABLE:16,17]. This was followed by involvement of 
blood (14.81%), respiratory tract (11.11%), skin and soft tissue (7.4%) and peritoneum 
(3.7%). 
In this study, all the gram negative bacteria isolated were sensitive to 
Imipenem[TABLE:18,19]and all Gram positive cocci were found sensitive to 
Vancomycin. [TABLE:20,21].ESBL production was detected in 30 of the 54 (55.55 %) 
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gram negative bacteria isolated[TABLE:22]. Among the ten strains of Staphylococcus 
aureus eight were found to be MRSA[TABLE:23]. Salmonella typhi was found sensitive 
to all the antibiotics tested.  
All the five Candida isolated were sensitive to Amphotericin B, Itraconazole, 
Fluconazole and Voriconazole. One Aspergillus flavus was also sensitive to 
Amphotericin B, Itraconazole and Voriconazole. [TABLE:24]. 
ANA was positive in 108 (98.18%) patients in the current study. Malaviya et al
[53]
 
in their study reported ANA positivity in 98% of SLE patients. The present study is 
comparable to the above study. In ANA detection by indirect IF using HEp 2 slides as 
substrate, the common pattern of nuclear staining observed was homogenous seen in 56 
(51.85%) patients[TABLE:26],  Kosaraju et al
[44]
in their study on auto antibody profile 
in South Indian SLE patients have also reported homogenous pattern in 55.5% of 
patients. The other ANA patterns identified in the present study were speckled 28 
(25.93%) and rim 24 (22.22%). Anti-ds DNA was positive in 70% of patients in this 
study [TABLE:27]. Similar result was also seen in the study of 75 SLE patients by Binoy 
et al. 
[69]
in which about 76% of patients had positive Anti-ds DNA. 77 (70%) SLE 
patients were positive for both ANA and Anti-ds DNA. 
In the present study low C3 levels were seen in 71 (64.5%) patients and low C4 
levels were observed in 61 (55%) patients. This result is in consistent with the study of 
H-Al Rayes
[26] 
in which C3 levels were decreased 65% of patients and C4 levels were 
decreased in 56% of patients. Both C3 and C4 levels were decreased in 60 (54.55%) SLE 
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patients. Low serum complement levels occur due to consumption of complement 
proteins as a result of immune complexes formation and deposition in various tissues. 
In the present study, dose of prednisolone ≥ 20 mg/day was associated with an 
increased risk of infection with a p value of < 0.05 which is statistically 
significant[TABLE:28]. The studies by Pryor et al
[72]
, Noel et al
[65]
, Bosch et al
[8]
, and 
Gladman et al
[22]
 have identified steroid intake as a risk factor for infection in SLE 
patients. The prednisolone dose had a facilitating effect on infection in patients with SLE 
by Ruiz- Irastorza et al
[25]
. The present study is comparable to the above mentioned 
studies. 
In the current study, the risk of infection was higher in patients receiving 
cyclophosphamide with a p value <0.05 which is statistically significant[TABLE:29]. 
Pryor et al
[72]
 reported a higher rate of infection in patients receiving cyclophosphamide 
and steroids. The present study is in line with the above study.  In this study, eight 
patients were on treatment with MMF out of which four developed infection. No 
significant association was found between infection and MMF with a p value more than 
0.05[TABLE:30]. In the study by Hu et al. 
[33]
it was found that the frequency of infection 
in SLE patients treated with MMF was less compared with patients on 
Cyclophosphamide (CPM) 
Out of 110 SLE patients, 3 patients died during the study period. All the three 
patients were female and were on immunosuppressive therapy.  Pneumonia was the cause 
of death in two patients and sepsis in one patient. Thus in all 3 cases, infection was the 
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cause of death. This finding is supported by studies by Barnatsky et al. 
[6]
and Doria et al. 
[17]
who have also reported infection as the major cause of death in SLE patients. 
From this study it is very clear that SLE patients are at high risk for infections due 
to various immunological dysfunctions and use of immunosuppressants. Therefore it is 
essential to evaluate all fevers in SLE patients, as the symptoms of SLE may mimic 
infection in many ways. Also the cautious use of steroids and other immunosuppressants 
is vital in controlling infections in SLE patients. 
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SUMMARY 
 A total of 110 SLE patients were included in this study. Samples were collected 
from these patients and processed according to standard methods. 
 The female:male ratio was 8:1. The median age of onset of SLE was 22 years. 
Duration of SLE ranged from 1 month to 19 years with a mean of 37 months.  
 Fifteen (13.6%) patients were children aged below 16 years. 
 The common clinical manifestations were arthritis (66.36%), fever (49.09%) and 
skin rash (44.55%) 
 40.91% of patients had Lupus Nephritis and Class IV LN (42.22%) was common. 
 Infectious episodes occurred in 60 (54.55%) patients. 
 Urinary tract was the most common site of infection followed by respiratory tract. 
 Bacterial infections were common accounting for 93.24% of infections. 
 Gram negative bacteria were the predominant organisms isolated. 
 Escherechia coli was the common uropathogen isolated from urinary tract. 
 Klebsiella pneumoniae(66.67%) was the most common isolate from respiratory 
tract. 
 Klebsiella pneumoniae (22.22%) and Pseudomonas aeruginosa (22.22%) were 
the common isolates from blood. 
 Pseudomonas aeruginosa (50%) was the most common isolate from skin and soft 
tissue. 
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 All the gram negative bacteria were sensitive to Imipenem. 
 55.55% of the gram negative bacteria were ESBL producers. 
 Out of the ten strains of Staphylococcus aureus, eight were found to be MRSA. 
 All the isolates of Staphylococcus aureus were sensitive to Vancomycin. 
 All the five Candida isolates were sensitive to Amphotericin B, Itraconazole, 
Fluconazole and Voriconazole. 
 Aspergillus flavus(1) was sensitive to Amphotericin B, Itraconazole and 
Voriconazole. 
 ANA was positive in 98.18 % of patients and homogenous was the most common 
pattern seen in indirect immunofluorescence. 
 Anti-ds DNA was positive in 70% of patients. 70% of SLE patients were positive 
for both ANA and Anti-ds DNA. 
 C3 and C4 levels were decreased in 63.64% and 55.45% of patients respectively. 
Both C3 and C4 levels were decreased in 54.55% of patients. 
 Prednisolone dose ≥ 20mg per day was associated with increased risk of infection. 
Also patients on Cyclophosphamide and Prednisolone had an increased risk of 
infection. No association was found between MMF and infection. 
 Out of 110 SLE patients, three patients died during the study period and infection 
was the major cause of death in all of them. 
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CONCLUSION 
The present study was done to identify the bacterial and fungal infections in 
patients with SLE, which is the most common autoimmune disease involving multiple 
organ systems. Among the patients with SLE, arthritis was the most common 
manifestation followed by fever and skin rash. Infections were present in 54.55% of SLE 
patients. It was found that bacterial infections were common than fungal infections and 
urinary tract was the most common site of infection. Escherechia coli was the most 
common bacteria isolated and Candida was the common fungus isolated. Study of 
antimicrobial susceptibility of the isolates showed resistance to wide range of antibiotics. 
Among the 53 Gram negative bacteria isolated, 30 were ESBL producers. Out of the 10 
Staphylococcus aureus isolated, 8 were found to be MRSA. In this study statistically 
significant association was found between infection and Prednisolone dose ≥ 20 mg/day 
and Prednisolone + cyclophosphamide. 
ANA was positive in 108 SLE patients and analysis of ANA patterns showed 
homogenous pattern to be the most common pattern. 77 patients were positive for both 
ANA and Anti-ds DNA. C3, C4 levels were found to be decreased in 63.64%, 55.45% of 
patients respectively. Both C3 and C4 levels were decreased in 60 SLE patients 
(54.55%). 
There are only a few published articles on infections in SLE from south India. 
Hence the present study shows that there is correlation between high dose steroids and 
infection in SLE patients. This study also emphasizes the need for evaluation of all fevers 
and judicious use of steroids and other immunosuppressants in SLE patients.  
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PROFORMA 
          
Name:              OP / IP No: 
Age:         Ward: 
Sex: 
Occupation: 
Address: 
 
Presenting complaints: 
 
Past Medical history: 
 
 
Treatment history: 
 
 
Associated Illness: 
 
 
CLINICAL MANIFESTATIONS 
 
1. Malar Rash 
2. Discoid Rash 
3. Photosensitivity 
4. Oral ulcers 
5. Arthritis 
6. Serositis 
7. Renal disorder 
a. Persistent Protenuria 
b. Cellular casts 
8. Neurologic disorder 
a. Headache 
b. Seizures 
c. Psychisis 
9. Haemotologic disorder 
10. Immunologic disorder 
11. Fever 
12. Skin rashes 
13. Alopecia 
 
LABORATORY EVALUATION 
 
1. Haemoglobin 
2. Total count 
3. Differential count 
4. ESR 
5. Blood sugar: Fasting, Postprandial 
6. Urea 
7. Creatinine 
8. Urine routine examination 
9. RF 
10. ANA 
11. dsDNA 
12. C3 / C4 Levels 
 
MICROBIOLOGICAL INVESTIGATION 
a. Direct examination 
 Gram stain 
 Wet mount 
 KOH mount 
 India Ink preparation 
b. Culture 
 Bacterial culture 
 Fungal culture 
c. Antimicrobial susceptibility pattern 
  APPENDIX 
A. STAINS AND REAGENTS 
 
I. Gram staining 
Methyl violet (2%) l0g Methyl violet in l00ml absolute alcohol in 
1litre of distilled water (primary stain) 
Grams Iodine l0g Iodine in 20g KI (fixative) 
Acetone Decolorizing agent 
Carbol fuchsin 1% Secondary stain 
 
II. Lactophenol cotton blue stain 
Lactic acid 20 ml 
Phenol 20ml 
Cotton blue (dye) 0.5g 
Glycerol 40ml 
Distilled water 20ml 
 
III. 10% KOH 
Potassium hydroxide l0g 
Glycerol l0ml 
Distilled water 80ml 
 
 
 
IV. India Ink Stain 
India Ink 150 ml 
Merthiolate (1:1000) 3 ml 
Tween 80 (1:10,000) 0.1 ml 
 
Mixed, filtered and kept in bottles. 
   
V. Ziehl-Neelsen stain 
 
 Ziehl-Neelsen Carbol fuchsin 
Basic fuchsin (powder) 
Phenol (crystalline) 
Absolute alcohol (ethanol) 
Distilled water 
 
5 g 
25 g 
50 ml 
500 ml 
 Sulphuric Acid 20 % 
 Loeffler’s methylene blue 0.5 % 
 
B. MEDIA USED 
 
1. MacConkey agar 
Peptone 20g 
Sodium taurocholate 5g 
Distilled Water 1 ltr 
Agar 20g 
2% neutral red in 50% ethanol 3.5ml 
10% lactose solution 100 ml 
 
 Dissolve peptone and taurocholate in water by heating. Add agar anddissolve it in 
steamer. Adjust pH to 7.5. Add lactose and neutral red shake welland mix.Heat in free 
steam (100°C) for 1 hour, then autoclave at 115°C for 15minutes. 
 
2. Blood agar (5% sheep blood agar) 
Peptone l0g 
NaCl 5 g 
Distilled water 1 Liter 
Agar 10 g 
 
Dissolve ingredients in distilled water by boiling, and add 5% sheepblood(sterile) 
at 55°C adjust pH to 7.4. 
 
3. Chocolate agar 
Sterile defibrinated blood 10 ml 
Nutrient Agar (melted) 100 ml 
 
When the temperature was about 75°C, sterile blood was added withconstant 
agitation. After addition of blood, kept in water bath and heating was continued till the 
blood changed tochocolate color. Cooled to about 50° C andpoured about 15ml into petri 
dishes with sterile precaution. 
 
4. Sabouraud’s dextrose agar 
Dextrose 40g 
Peptone l0g 
Agar 20g 
Distilled water l000ml 
 
pH = 5.6 
 
5. Mueller – Hinton Agar 
Beef infusion 300ml 
Caeseinhydrolysate 17.5g 
Starch 1.5g 
Agar 10g 
Distilled water 1ltr 
 
pH = 7.4. Sterilise by autoclaving at 121ºC for 20 minutes. 
 
6. Cystine lactose electrolyte – deficient medium 
Peptone 4 g 
Tryptone 4 g 
Meat extract powder 3 g 
Lactose 10 g 
L- cystine 0.128 g 
Bromothymol blue 0.02 g 
Agar 15 g 
Water 1 L 
 
Sterilize by autoclaving at 121ºC for 20 minutes. 
      
7. Lowenstein Jensen Medium 
Mineral salt solution 600 ml 
Malachite green solution 20 ml 
Beaten egg  
 
After mixing the complete medium distribute in 5 ml amounts in sterile screw 
capped bottles. Lay the bottles on their sides and inspissate at 80
0
C – 850C for 3 
consecutive days. 
 
8. Xylose lysine deoxycholate agar 
Yeast extract 3.0 g 
Xylose 3.75 g 
Lactose 7.5 g 
Sucrose 7.5 g 
l-Lysine HCL 5.0 g 
Sodium chloride 5.0 g 
Sodium deoxycholate 2.5 g 
Sodium thiosulphate 6.8 g 
Ferric ammonium citrate 0.8 g 
Phenol red 0.08 g 
Agar 15 g 
Water 1 L 
 
pH 7.4. Sterilize by autoclaving at 121ºC for 20 minutes. 
 
9. Selenite F broth 
Sodium hydrogen selenite 4 g 
Peptone 5 g 
Lactose 4 g 
Disodium hydrogen phosphate 9.5 g 
Sodium dihydrogen phosphate 0.5 g 
Sterile water 1 L 
 
Steam for 20 min at 100 ºC 
 
 
 
10. BHI broth 
Brain infusion broth 250 ml 
Heart infusion broth 750 ml 
Sodium polyanetholsulphonate 0.25 g 
 
pH: 7.4 to 7.6. Sterilize by autoclaving at 121ºC for 20 minutes 
 
 
C. MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION 
 
1. Oxidase Reagent 
Tetra methyl p-phenylene diamine dihyrochloride- 1% aqueous solution. 
2. Catalase Reagent 
3% hydrogen peroxide 
3. Indole test 
Kovac’s reagent contains the following: 
 
Amyl or isoamyl alcohol 150ml 
Para dimethyl amino benzaldehyde 10g 
Concentrated hydrochloric acid 50ml 
 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare insmall 
quantities and store in the refrigerator. Shake gently before use. 
 
 4. Christensen’s Urease test medium  
Peptone 1g 
Sodium chloride 5g 
Dipotassium hydrogen phosphate 2g 
Phenol red   6ml 
Agar 20g 
Distilled water   1 ltr 
10% sterile solution of glucose l0ml 
Sterile 20% urea solution l00ml 
 
Sterilize the glucose and urea solutions by filtration. Prepare the basalmedium 
without glucose and urea, adjust to pH 6.8-6.9 and sterilize byautoclaving in a flask at 
121°C for 30 minutes. Cool to about 50°C, add the glucose and urea, and tube the 
medium as slopes. 
 
5. Simmon’s Citrate Medium 
Koser’s medium 1 ltr 
Agar   20g 
Bromothymol blue 0.2% 40ml 
 
 Dispense, autoclave at 121°C for 15 min and allow to set as slopes. 
 
 6. Triple Sugar Iron medium 
Beef extract 3g 
Yeast extract 3g 
Peptone 20g 
Glucose 1g 
Lactose l0g 
Sucrose l0g 
Ferric citrate 0.3g 
Sodium chloride 5g 
Sodium thiosulphate 0.3g 
Agar 12g 
Phenol red 0.2% solution l2ml 
Distilled water 1 ltr 
 
Heat to dissolve the solids, add the indicator solution, mix and tube. Sterilize 
at121°C for 15 minutes and cool to form slopes with deep butts. 
 
7. Glucose phosphate broth 
Peptone 5g 
Dipotassium hydrogen phosphate 5g 
Water 1 ltr 
Glucose 10% solution 50ml 
Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter, dispense in 
5mlamounts and sterilize at 121°C for 15min. Sterilize the glucosesolution by filtration 
and add 0.25ml to each tube. 
 
Methyl Red Reagent 
Methyl Red 10mg 
Ethyl alcohol 30ml 
Distilled water 20ml 
 
Voges Proskauer Reagent 
Reagent A: 
Alpha naphthol 5g 
Ethyl alcohol 100ml 
 
Reagent B: 
Potassium hydroxide 40g 
Distilled water 100ml 
 
8. Peptone water fermentation test medium 
To the basal medium of peptone water, add sterilized1% sugars, bromothymol blue 
indicator with Durham’s tube. 
Basal medium: Peptone water 
 Sugar solutions: 
Sugar 1ml 
Distilled water l00ml 
 
pH = 7.6. 
9. Mannitol motility medium 
Agar 5g 
Peptone 1g 
Potassium nitrate 1 g 
Mannitol 2 g 
Phenol red indicator  
Distilled water l000ml 
 
pH 7.2 
10. Phenolphthalein diphosphate agar 
 Sterilize a 1% aqueous solution of sodium phenolphthalein diphosphateby 
filtration and store at 4ºC 
 Add 10ml of this solution to 1000ml melted nutrient agar cooled to 50ºCand pour 
plates 
 Grow the staphylococcus overnight at 37ºC on the medium 
 Invert the plate and pour a few drops of ammonia solution SG 0.88 intothe lid 
 Read as positive a culture whose colonies turn bright pink within a 
fewminutes.The color soon fades. 
11. Potassium nitrate broth 
Potassium nitrate (KN03) 0.2g 
Peptone 5.0g 
Distilled water 100ml 
 
The above ingredients were mixed and transferred into tubes in 5 mlamount and 
autoclaved. 
12. Phenyl alanine deaminase test 
Yeast Extract 3g 
DL-Phenylalanine 2 g 
Disodium hydrogen phosphate l g 
Sodium Chloride 5 g 
Agar 12 g 
Distilled water 1 lr 
 
pH 7.4 
Distributed in tubes and sterilized by autoclaving at 121°C for 15minutes, allowed 
to solidify as long slopes. 
13. Sugar fermentation medium 
Peptone 15g 
Andrade’s indicator 10 ml 
Sugar to be tested 20g 
Water 1liter 
 
Andrade’s indicator is prepared from 0.5% aqueous acid fuchsin to which 
sufficient 1M sodium hydroxide has been added to turn the color of thesolution 
yellow.Dissolve the peptone and Andrade’s indicator in 1liter of water and add20g of the 
sugar; sugars to be tested generally include glucose, sucrose, lactoseand maltose. 
Distribute 3ml amounts in standard test tubes containing aninverted Durham tube. 
Sterilize by steaming at 100
0
C for 30 minutes on 3consecutive days. 
 
 
ABBREVIATIONS 
ANA  - Antunuclear Antibody 
aPL  - Antiphospholipid Antibody 
ATCC  - American Type Culture Collection 
BAL  - Bronchoalveolar lavage 
CIE  - Counter Immunoelectrophoresis 
CLSI  - Clinical and Laboratory Standards Institute 
CPM  - Cyclophosphamide 
DDST  - Double disk diffusion synergy test 
ELISA  - Enzyme linked Immunosorbent Assay 
ESBL  - Extended Spectrum Beta Lactamase 
FANA  - Indirect immunofluorescence Antinuclear antibody test  
HLA  - Human Leukocyte antigen 
ID  - Immunodiffusion 
LN  - Lupus Nephritis 
MHC  - Major Histocompatibility Complex 
MIC  - Minimum Inhibitory Concentration 
MMF  - Mycophenolate mofetil 
MRSA  - Methicillin resistant Staphylococcus aureus 
NSAID - Nonsteroidal antiinflammatory drugs 
PCT  - Phenotypic confirmation test 
PBS  - Phosphate buffered saline 
RIA  - Radioimmunoassay 
RID  - Radial immunodiffusion 
SLE  - Systemic lupus erythematosus 
UTI  - Urinary tract infection 
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Sl # OP / IP # Age Sex Episodes of Infection Site of Infection Pathogens ESBL MRSA Immune Profile C3 Levels C4 Levels
1 82895 22 Female One Respiratory Tract Pseudomonas aeruginosa Anti-dsDNA Decreased
2 82111 52 Female One Urinary Tract Escherichia coli Yes
3 93958 47 Female One Urinary Tract Escherichia coli Yes Anti-dsDNA
Blood No Growth
CNS No Growth
4 105646 24 Male One Skin and Soft Tissue Staphylococcus aureus Yes Anti-dsDNA Decreased
Respiratory Tract No Growth
Urinary Tract No Growth
5 110337 17 Female One Ear Aspergillus flavus Anti-dsDNA
6 2317/06 26 Female One Urinary Tract Escherichia coli Anti-dsDNA Decreased
7 53603 30 Female One Respiratory Tract Staphylococcus aureus Yes Anti-dsDNA
8 48830 23 Female One Blood Salmonella Typhi Anti-dsDNA Decreased
Urinary Tract No Growth
9 55319 24 Female Urinary Tract No Growth Anti-dsDNA
10 54541 47 Female Respiratory Tract No Growth
11 52311 30 Female Respiratory Tract No Growth Anti-dsDNA
12 1787/11 28 Female One Urinary Tract Escherichia coli Anti-dsDNA Decreased
13 6177 35 Female One Urinary Tract Pseudomonas aeruginosa Yes Anti-dsDNA Decreased Decreased
Blood Pseudomonas aeruginosa Yes
14 52045 32 Female Respiratory Tract No Growth Anti-dsDNA Decreased Decreased
15 53703 24 Female One Respiratory Tract Klebsiella pneumoniae Yes
16 51941 33 Female Urinary Tract No Growth Anti-dsDNA
17 53705 15 Female Urinary Tract No Growth
18 7739 22 Female Urinary Tract No Growth Anti-dsDNA
19 8236 46 Female One Skin and Soft Tissue Candida albicans Anti-dsDNA Decreased Decreased
20 8117 30 Female Urinary Tract No Growth
21 10134 41 Male One Respiratory Tract Staphylococcus epidermidis Anti-dsDNA
22 9154 25 Female Blood No Growth
Urinary Tract No Growth
23 52223 26 Female Urinary Tract No Growth Anti-dsDNA
24 52234 34 Female Respiratory Tract No Growth Anti-dsDNA Decreased Decreased
25 54921 18 Female One Blood Klebsiella pneumoniae Anti-dsDNA Decreased Decreased
Urinary Tract No Growth
26 6031 15 Female Respiratory Tract No Growth Anti-dsDNA Decreased
27 17494 21 Female One Urinary Tract Citrobacter freundii Yes
Blood No Growth
GIT No Growth
28 11677 19 Female One Urinary Tract Candida albicans Anti-dsDNA
29 46332 32 Female Urinary Tract No Growth
30 55193 24 Female One Skin and Soft Tissue Staphylococcus aureus Yes
31 19256 16 Female One Blood Pseudomonas aeruginosa Anti-dsDNA Decreased Decreased
32 26798 13 Male Urinary Tract No Growth
33 26194 23 Female Two Respiratory Tract Klebsiella pneumoniae Yes Anti-dsDNA Decreased Decreased
Blood Acinetobacter baumannii
34 100504 19 Male Two Blood No Growth
Respiratory Tract Klebsiella pneumoniae
Urinary Tract Escherichia coli Yes
35 29686 30 Female One Urinary Tract Escherichia coli Yes Anti-dsDNA
36 31473 33 Female GIT No Growth
37 1290/11 14 Female Urinary Tract No Growth Anti-dsDNA
38 32595 48 Female One Blood No Growth Decreased
Urinary Tract Staphylococcus aureus Yes
39 46897 35 Female One Urinary Tract Escherichia coli Yes Decreased
40 38063 23 Female Two Urinary Tract Escherichia coli Yes Anti-dsDNA
Blood Staphylococcus aureus
41 36329 27 Female One Urinary Tract Klebsiella oxytoca Yes Anti-dsDNA Decreased Decreased
42 1754/10 23 Female Two Urinary Tract Staphylococcus epidermidis Anti-dsDNA Decreased Decreased
Urinary Tract Escherichia coli Yes
43 1891/09 22 Female One Urinary Tract Klebsiella pneumoniae Anti-dsDNA Decreased Decreased
44 38642 24 Female One Blood Staphylococcus aureus Yes Decreased
Urinary Tract No Growth
Skin and Soft Tissue No Growth
45 40523 40 Female GIT No Growth Anti-dsDNA
46 41278 33 Male One Oral Cavity Candida albicans Decreased
Blood No Growth
47 42196 36 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
48 39432 16 Female Urinary Tract No Growth Decreased Decreased
49 41809 22 Female Urinary Tract No Growth Anti-dsDNA
Blood No Growth
50 42274 25 Female One Skin and Soft Tissue Pseudomonas aeruginosa Yes Decreased Decreased
51 41789 19 Female One Urinary Tract Acinetobacter baumannii Anti-dsDNA
Blood No Growth
52 43418 30 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
53 43050 40 Female Two Blood Klebsiella pneumoniae Anti-dsDNA
Urinary Tract Escherichia coli Yes
CNS No Growth
54 68891 30 Female One Urinary Tract Proteus mirabilis Anti-dsDNA Decreased
55 45305 30 Female One Respiratory Tract Klebsiella pneumoniae Yes Decreased Decreased
56 47569 32 Female GIT No Growth Anti-dsDNA Decreased Decreased
57 45480 23 Female GIT No Growth
CNS No Growth
58 45732 27 Female Three Urinary Tract Pseudomonas aeruginosa Anti-dsDNA Decreased Decreased
Urinary Tract Staphylococcus aureus Yes
Respiratory Tract Klebsiella pneumoniae
59 2301/09 16 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
60 47620 39 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
61 51296 20 Female One Urinary Tract Escherichia coli Yes Anti-dsDNA Decreased Decreased
62 52028 37 Female Urinary Tract No Growth Decreased Decreased
63 52583 15 Female One Urinary Tract Pseudomonas aeruginosa Anti-dsDNA Decreased Decreased
Skin and Soft Tissue Staphylococcus aureus
64 51911 23 Female Urinary Tract No Growth Anti-dsDNA
65 53976 24 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
66 55212 16 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
67 53418 21 Female One Urinary Tract Escherichia coli Yes Anti-dsDNA Decreased Decreased
68 47302 24 Female Urinary Tract No Growth
69 53926 32 Male Urinary Tract No Growth Anti-dsDNA Decreased Decreased
Blood No Growth
70 56538 10 Male One Oral Cavity Candida albicans Decreased Decreased
71 89217 21 Male Blood No Growth Anti-dsDNA Decreased Decreased
Urinary Tract No Growth
Respiratory Tract No Growth
72 4679/12 22 Female One Urinary Tract Candida tropicalis Anti-dsDNA Decreased Decreased
73 96615 28 Female One Urinary Tract Enterococcus faecalis Anti-dsDNA Decreased Decreased
Respiratory Tract Klebsiella pneumoniae
74 94300 21 Female One Urinary Tract Escherichia coli Yes Anti-dsDNA Decreased Decreased
Skin and Soft Tissue Pseudomonas aeruginosa Yes
75 71885 14 Female One Urinary Tract Escherichia coli Yes Anti-dsDNA Decreased Decreased
76 63511 19 Female Two Urinary Tract Escherichia coli Yes Anti-dsDNA Decreased Decreased
Urinary Tract Pseudomonas aeruginosa Yes
77 4048 15 Female One Urinary Tract Escherichia coli Decreased Decreased
78 63167 12 Female One Urinary Tract Enterococcus faecalis Anti-dsDNA Decreased Decreased
79 65316 25 Female One Skin and Soft Tissue Pseudomonas aeruginosa Anti-dsDNA Decreased Decreased
80 68890 28 Female One Peritoneum Pseudomonas aeruginosa Yes Anti-dsDNA Decreased Decreased
81 71028 21 Female One Respiratory Tract Pseudomonas aeruginosa Yes Anti-dsDNA Decreased Decreased
82 75580 18 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
83 71883 17 Female One Urinary Tract Escherichia coli Anti-dsDNA Decreased Decreased
84 69794 20 Female One Blood Staphylococcus epidermidis Decreased Decreased
Urinary Tract No Growth
85 87361 22 Female One Urinary Tract Escherichia coli Yes Anti-dsDNA
86 85300 25 Female Two Urinary Tract Staphylococcus aureus Yes Anti-dsDNA Decreased Decreased
Urinary Tract Staphylococcus aureus Yes
87 260/08 37 Male Urinary Tract No Growth Anti-dsDNA
Respiratory Tract No Growth
Blood No Growth
88 49911 19 Male One Respiratory Tract Klebsiella pneumoniae Decreased Decreased
89 26155 23 Male One Skin and Soft Tissue Pseudomonas aeruginosa Yes Anti-dsDNA
90 101164 21 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
91 100854 26 Male Urinary Tract No Growth Decreased Decreased
92 93118 18 Female Two Urinary Tract Escherichia coli Anti-dsDNA
Urinary Tract Proteus mirabilis
93 47565 25 Female One Ear Pseudomonas aeruginosa Yes Anti-dsDNA
94 89891 22 Female Respiratory Tract No Growth Anti-dsDNA Decreased Decreased
95 1520/09 25 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
96 90785 18 Female Urinary Tract No Growth Anti-dsDNA
97 3720/05 30 Female One Urinary Tract Klebsiella pneumoniae Anti-dsDNA Decreased Decreased
98 108788 16 Female Urinary Tract No Growth Decreased Decreased
99 55390 13 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
100 88937 27 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
101 94736 19 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
102 2525/10 25 Female Respiratory Tract No Growth Decreased Decreased
103 54594 38 Female Urinary Tract No Growth Decreased Decreased
104 58903 26 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
105 109635 28 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
106 11315 28 Female One Urinary Tract Escherichia coli Yes Anti-dsDNA Decreased Decreased
107 108611 24 Female Blood No Growth Decreased Decreased
Urinary Tract No Growth
Respiratory Tract No Growth
108 84898 22 Female Urinary Tract No Growth Anti-dsDNA Decreased Decreased
109 8000 27 Female Urinary Tract No Growth Decreased Decreased
110 53976 24 Female One Respiratory Tract Klebsiella pneumoniae Yes Decreased
